---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description. Covers Product description and Place of product in therapy. 383 evidence topics quoted from 249 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; BLA submitted September 2026 under the accelerated approval pathway, with a PDUFA target action date in May 2027

> “In September 2026, we announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (the “FDA”) for the accelerated approval of ifezuntirgene inilparvovec as well as the submission of a marketing authorization application (“MAA”) for ifezuntirgene inilparvovec to the United Kingdom’s (“UK”) Medicines and Healthcare products Regulatory Agency (“MHRA”).”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

> “The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Commercial launch preparation

> “As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

> “The $2.4 million increase was primarily driven by a higher headcount following employee recruitment to support the potential commercial launches of ifezuntirgene inilparvovec”
> “The increase was primarily related to expenses incurred to support the preparation of a potential commercialization of ifezuntirgene inilparvovec”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-4"></a>

##### FDA acceptance of the BLA with Priority Review, November 2026

> “On November 2 2026, we announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-5"></a>

##### BLA submission in August 2026 and acceptance in October 2026: Form 10-Q statement

> “We submitted our BLA for ifezuntirgene inilparvovec to the FDA in August 2026 and the FDA accepted the application for review in October 2026, with a PDUFA target action date of May 1, 2027.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-6"></a>

##### Advisory committee meeting tentatively planned

> “In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting.”
> “The Company will be notified once the date and timelines have been finalized.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-7"></a>

##### Confirmatory study: alignment with the FDA on key design elements, November 2026

> “The Company and FDA have aligned on key elements of the confirmatory study design.”
> “The confirmatory trial remains a key priority, with screening anticipated to begin by year end and the study is expected to be well underway by the time of potential approval.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.1-8"></a>

##### BLA submission and priority review request, September 2026

> “uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease.”
> “The Company has requested priority review for the BLA. If granted, priority review would shorten the FDA review cycle to six months following the FDA’s 60-day BLA filing review period.”

Source: [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)

<a id="topic-2.1.1-9"></a>

##### Four-year data not included in the marketing applications

> “The applications submitted to the FDA and MHRA predated the subsequently reported 48-month topline results, and therefore the 48-month topline results were not part of the BLA or MAA.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-10"></a>

##### Type B meeting minutes, July 2026

> “Official meeting minutes received in July 2026 confirmed that the FDA and the Company reached alignment that a Biologics License Application (BLA) submission under the accelerated approval pathway for AMT-130, based on the existing clinical data, is reasonable.”
> “The FDA also stated that, in accordance with the FDA’s draft public guidance for accelerated approvals, the confirmatory study should be feasible to conduct within a reasonable timeline and be well underway, and potentially fully enrolled, at the time of accelerated approval.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-11"></a>

##### Type B meeting, June 2026

> “the FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a Biologics License Application (BLA) for the accelerated approval of AMT-130 in Huntington’s disease.”
> “In addition, the FDA seeks to align on the confirmatory study design prior to the BLA submission, including consideration of concurrent control on standard-of-care therapy instead of a sham procedure.”

Source: [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)

<a id="topic-2.1.1-12"></a>

##### BLA submission timing: third quarter of 2026, June 2026, superseded in September 2026

> “The Company intends to submit the BLA in the third quarter of 2026.”

Source: [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons)

> “Discussions with the FDA to align on the confirmatory study design and analysis are underway and the Company expects to submit a BLA in the third quarter of 2026.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-13"></a>

##### FDA position after the January 2026 Type A meeting, March 2026, superseded in June 2026

> “today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).”
> “The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130. The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study.”
> “uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.”

Source: [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2)

<a id="topic-2.1.1-14"></a>

##### Type A meeting scheduled, January 2026

> “today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease.”

Source: [uniQure press release, Type A meeting scheduled (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-type-meeting-scheduled-fda)

<a id="topic-2.1.1-15"></a>

##### Pre-BLA meeting minutes, December 2025

> “today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease (HD).”
> “In the final meeting minutes, and consistent with uniQure’s November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.”

Source: [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1)

<a id="topic-2.1.1-16"></a>

##### BLA submission timing: unclear, November 2025, superseded in June 2026

> “Though final meeting minutes have not yet been received, based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.”
> “This is a key shift from prior communications with the FDA in multiple Type B meetings over the past year. Consequently, the timing of the BLA submission for AMT-130 is now unclear.”

Source: [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0)

<a id="topic-2.1.1-17"></a>

##### BLA submission timing: first quarter of 2026, June 2025, superseded in November 2025

> “Q1 2026: submit BLA with a request for priority review designation”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

> “We are eager to discuss the data with the FDA at our pre-BLA meeting expected later this year, with the goal of submitting a BLA in the first quarter of 2026.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-2.1.1-18"></a>

##### U.S. launch timing: 2026, September 2025, superseded in November 2025

> “uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

> “We believe this transaction enhances our financial flexibility to fund the potential commercial launch of AMT-130 in the United States, anticipated in 2026,”

Source: [uniQure press release, debt refinancing (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-refinancing-existing-50-million-debt-and)

<a id="topic-2.1.1-19"></a>

##### FDA interactions on the statistical analysis plan, 2025

> “In the second quarter of 2025, the Company held a Type B meeting with the FDA to discuss the proposed use of external control data and the prospectively defined statistical analysis plan (SAP) in support of the planned BLA submission for AMT-130.”
> “The FDA agreed that the primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

> “In July 2025, the Company submitted the final SAP to the FDA. Additionally, the Company initiated its PPQ campaign to support the planned BLA submission.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

<a id="topic-2.1.1-20"></a>

##### FDA interactions on chemistry, manufacturing and controls, 2025

> “In the first quarter of 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of the planned BLA submission for AMT-130. The FDA agreed that validation of the AMT-130 manufacturing process should be possible using experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX®) process, complemented with additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.”
> “The FDA also agreed with the Company’s proposed drug product release testing plan, including the proposed potency assay, pending completion of qualification and specification setting activities.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.1.1-21"></a>

##### FDA alignment on the accelerated approval pathway, December 2024, superseded in November 2025

> “As part of uniQure’s Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study.”
> “The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain (NfL) measured in cerebrospinal fluid (CSF) may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-2.1.1-22"></a>

##### Designations held: current statement

> “Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “In addition to the Breakthrough Therapy designation, the FDA previously granted RMAT designation, Orphan Drug designation and Fast Track designation to AMT-130.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-23"></a>

##### Breakthrough Therapy designation: April 2025

> “In April 2025, we announced that the FDA granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease. The Breakthrough Therapy designation was supported by clinical data from the ongoing Phase I/II trials of AMT-130 for the treatment of Huntington’s disease showing the potential for meaningful slowing of disease progression.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-24"></a>

##### Regenerative Medicine Advanced Therapy designation: May 2024

> “The FDA granted uniQure RMAT designation for AMT-130 in May 2024, stating that preliminary clinical data from the ongoing Phase I/II studies indicate AMT-130 has the potential to address unmet medical needs for the treatment of Huntington’s disease.”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

> “The designation follows the FDA’s review of interim Phase I/II clinical data for AMT-130 announced in December 2023 and is based on an analysis comparing these 24-month clinical data to a non-concurrent criteria-matched natural history cohort.”

Source: [uniQure press release, FDA RMAT designation (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-regenerative-medicine-advanced-therapy-rmat)

<a id="topic-2.1.1-25"></a>

##### Fast Track designation: April 2019

> “April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130, the Company’s gene therapy candidate for the treatment of Huntington’s disease.”

Source: [uniQure press release, FDA Fast Track designation (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-fast-track-designation-amt-130-gene-therapy)

<a id="topic-2.1.1-26"></a>

##### Orphan drug designation: FDA, September 2017

| Field | Quoted record |
| --- | --- |
| Generic name | “adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene” |
| Date designated | “09/27/2017” |
| Orphan designation | “Treatment of Huntington's disease” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “uniQure Biopharma B.V.” |

Source: [FDA orphan drug designation record for AMT-130 (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=525216)

<a id="topic-2.1.1-27"></a>

##### Orphan designation: European Commission, January 2018

> “On 17 January 2018, orphan designation (EU/3/17/1957) was granted by the European Commission to uniQure biopharma B.V., the Netherlands, for adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene (also known as AAV5-MiHTT) for the treatment of Huntington's disease.”

Source: [EMA orphan designation EU/3/17/1957 (2018)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1957)

> “We have been granted orphan drug exclusivity for AMT-130 for the treatment of Huntington’s disease subject to the conditions applicable to orphan drug exclusivity in the EU. No pre-marketing authorization orphan designation step is required in the UK, but similar criteria will apply at the time of MA.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.1-28"></a>

##### PRIority MEdicines (PRIME) designation

No evidence found.

<a id="topic-2.1.1-29"></a>

##### UK marketing authorization application: submitted and validated, third quarter of 2026

> “The Company also announced that its Marketing Authorisation Application (MAA) for ifezuntirgene inilparvovec has been submitted to the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA).”

Source: [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)

> “In the third quarter of 2026, the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorization Application (MAA) for ifezuntirgene inilparvovec, which was submitted to the MHRA earlier in the quarter.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-30"></a>

##### UK MAA timing: third quarter of 2026, April 2026, superseded in September 2026

> “today announced the Company held a Pre-Submission Meeting with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) and plans to submit a Marketing Authorization Application (MAA) for AMT-130 for the treatment of Huntington’s disease in the third quarter of 2026.”
> “During the meeting, the Company and MHRA discussed the data package and manufacturing requirements to support a MAA submission for AMT-130.”

Source: [uniQure press release, MHRA pre-submission meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-successful-uk-mhra-pre-submission-meeting-amt)

<a id="topic-2.1.1-31"></a>

##### European Union and other markets: statements on regulatory pathways

> “In addition to continuing to partner with the FDA on progressing AMT-130 for the treatment of Huntington’s disease, uniQure plans in parallel to progress discussions with other regulatory agencies, including in the European Union and United Kingdom.”

Source: [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0)

> “The Company is also actively pursuing additional regulatory pathways in international markets for potential registration of AMT-130 and expects to provide further updates in the second half of 2026.”

Source: [uniQure press release, MHRA pre-submission meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-successful-uk-mhra-pre-submission-meeting-amt)

<a id="topic-2.1.1-32"></a>

##### Investigational New Drug application effective, January 2019

> “today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study.”

Source: [uniQure press release, IND clearance (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-clearance-investigational-new-drug)

<a id="topic-2.1.1-33"></a>

##### Financing: cash position and runway into 2030, September 2026

> “As of September 30, 2026, we had cash and cash equivalents, restricted cash and investment securities of $770.0 million. We believe these resources will be sufficient to fund our projected operating expenses into 2030, including costs associated with the commercial launches and confirmatory study of ifezuntirgene inilparvovec, ongoing clinical trials of ifezuntirgene inilparvovec, AMT-191 and AMT-260, and potential investments to advance certain pipeline candidates into late-stage development.”
> “We have based our estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, and as such, we may require additional funding.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-34"></a>

##### Financing: Hercules term loan terms tied to BLA approval

> “This includes up to $100.0 million in additional availability under our Hercules senior secured term loan facility, which becomes accessible upon BLA approval for ifezuntirgene inilparvovec prior to September 30, 2027, subject to confirmatory trial requirements remaining on track.”
> “The interest-only period will be extended to October 1, 2029 if the BLA for ifezuntirgene inilparvovec is approved prior to October 1, 2028.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.1-35"></a>

##### Financing: June 2026 public offering

> “In June 2026, the Company closed an upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, including the full exercise of the underwriters’ option to purchase additional shares. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were $259 million.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-2.1.1-36"></a>

##### Cash runway into the second half of 2029, March 2026, superseded in July 2026

> “As of December 31, 2025, the Company had cash, cash equivalents and current investment securities of $622.5 million. The Company expects that cash, cash equivalents and investment securities will be sufficient to fund operations into the second half of 2029.”

Source: [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent)

<a id="topic-2.1.1-37"></a>

##### Securities class action

> “On February 10, 2026, a class action complaint captioned Christopher Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed against us, certain of our executive officers and another party (collectively, “Defendants”) in the United States District Court for the Southern District of New York.”
> “Lead Plaintiff seeks unspecified damages allegedly caused by purported false and misleading statements and omissions with respect to the import and viability of data from our Phase I/II study of ifezuntirgene inilparvovec and available pathways to regulatory approval. Defendants’ motion to dismiss the amended complaint is currently due November 4, 2026.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: uniQure

> “Ifezuntirgene inilparvovec (also known as AMT-130) is our novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes our proprietary, gene-silencing miQURE® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name and development code

> “Our investigational gene therapy candidate ifezuntirgene inilparvovec (AMT-130) consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene, leveraging our proprietary miQURE™ silencing technology.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

<a id="topic-2.1.2.1-3"></a>

###### Nonproprietary name: WHO proposed International Nonproprietary Name and substance description

> “a recombinant, replication deficient adeno-associated virus serotype 5 (AAV5) vector encoding a microRNA (miRNA) targeting the exon 1 of human huntingtin protein (HTT) mRNA (miHTT).”

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Product name, product code, and descriptive name in the EU clinical trial record

| Field | Quoted record |
| --- | --- |
| Product name | “rAAV5-miHTT” |
| Product code | “AMT-130” |
| Other descriptive name | “ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.1-5"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class: AAV-based gene therapy using the miQURE gene-silencing platform

> “AMT-130 is the first AAV-based gene therapy for the treatment of Huntington’s disease to have entered into clinical development.”
> “miQURE-based gene therapy candidates, such as AMT-130, incorporate proprietary, therapeutic miRNA constructs that can be delivered using AAVs to potentially provide long-lasting activity.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-7"></a>

###### Licensing: miQURE platform technology from Cold Spring Harbor Laboratory

> “Our miQURE gene silencing platform, based on exclusively licensed technology from Cold Spring Harbor Laboratory (“CSHL”), is designed to degrade mutated genes without producing a “passenger strand” thereby mitigating potential off-target toxicity and induce silencing of the mutated gene in the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-8"></a>

###### Intellectual property: patent families covering AMT-130 and its formulation

> “We own three published patent families directed to gene therapy treatment of Huntington’s disease, including AMT-130 and its formulation.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-9"></a>

###### Manufacturing: contract manufacturing by Genezen after the 2024 facility sale

> “Under the proposed transaction, Genezen will be responsible for manufacturing global commercial supply of HEMGENIX® for CSL and providing development and manufacturing services to support uniQure’s investigational gene therapies.”

Source: [uniQure press release, sale of manufacturing facility to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-sale-commercial-manufacturing-facility-genezen)

> “Additionally, this transaction provides uniQure continued and preferred access to world-class gene therapy manufacturing capabilities to advance our gene therapy product candidates and enables us to focus our future investments on projects that have the potential to meaningfully increase shareholder value.”

Source: [uniQure press release, closing of sale to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-closing-sale-manufacturing-facility-genezen)

> “We currently rely and expect to continue to rely on third parties to manufacture our product candidates, and these third parties may not perform satisfactorily or may fail to comply with these regulations or maintain these approvals.”
> “Our proprietary manufacturing processes leveraging insect cells and baculoviruses to produce AAV-based gene therapies are highly complex and regularly subject to variation or production difficulties.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Pharmaceutical form and route of administration

| Field | Quoted record |
| --- | --- |
| Active substance | “ifezuntirgene inilparvovec” |
| Condition | “Treatment of Huntington’s disease” |
| Pharmaceutical form | “Suspension for infusion” |
| Route of administration | “INTRACEREBRAL USE” |
| Applicant | “uniQure biopharma B.V.” |

Source: [MHRA paediatric investigation plan waiver decision (2026)](https://cms.mhra.gov.uk//system/files/2026-07/mhra-102322-pip01-26.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Pharmaceutical form and concentrations in the European phase Ib/II study

| Field | Quoted record |
| --- | --- |
| Pharmaceutical form | “Solution for infusion” |
| Concentration, first IMP | “2 x 10e12 gc/mL” |
| Concentration, second IMP | “2 x 10e13 gc/mL” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.2-3"></a>

###### Dose levels administered in the phase I/II studies: vector genomes per participant

> “AMT-130 was generally well tolerated in the treated patients at the lower dose of 6x1012 vector genomes (vg).”
> “The safety profile of AMT-130 in the low-dose cohort to date supports continued enrollment of patients in the higher-dose cohort of 6x1013 vg.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-2.1.2.2-4"></a>

###### Administration device: stereotactic MRI-guided cannula

> “Certain of our product candidates require medical devices for administration, such as AMT-130 and AMT-260, each of which requires a stereotactic, magnetic resonance imaging guided cannula.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.2-5"></a>

###### Formulation composition, fill volume, and storage conditions

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO International Nonproprietary Name classification

> “gene therapy (Huntington's disease)”

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.4-2"></a>

###### U.S. regulatory classification: biologic and gene therapy reviewed by CBER

> “We believe that all our product candidates will be regulated as biological products, or biologics, and in particular, as gene therapies, and will be subject to such requirements and regulations under U.S. and foreign laws.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “Our alignment reflects the strength of our data and collaborative discussions with the staff and senior management at FDA’s Center for Biologics Evaluation and Research (CBER).”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-2.1.2.4-3"></a>

###### EU classification: advanced therapy investigational medicinal product, gene therapy

| Field | Quoted record |
| --- | --- |
| Advanced Therapy IMP (ATIMP) | “Yes” |
| Gene therapy medical product | “Yes” |
| Committee on Advanced therapies (CAT) has issued a classification for this product | “No” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.4-4"></a>

###### AHFS and Anatomical Therapeutic Chemical classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication submitted in the BLA: treatment of Huntington's disease under the accelerated approval pathway

> “today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.2.5-2"></a>

###### Investigational status: no approved indication

> “AMT-130 is an investigational agent currently being studied in the treatment of Huntington’s Disease.”
> “Its safety and efficacy have not been established and it has not been approved by the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), or any other regulatory body.”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.1.2.5-3"></a>

###### Population studied: adults aged 25 to 65 years with early manifest Huntington's disease

> “We are currently conducting a multi-center randomized, controlled Phase I/II clinical trial for AMT-130 in the U.S. (the “U.S. study”), as well as an open-label Phase Ib/II study in Europe (the “European study”) with the same early-manifest criteria for Huntington’s disease as the U.S. study.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “Patients with a definitive clinical diagnosis of early manifest HD”
> “Males and females, between the ages of 25 to 65 years old”
> “CAG repeat expression of ≥40”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism: AAV5 vector carrying a microRNA that non-selectively lowers human huntingtin

> “The vector acts as a delivery system and is based on a non-disease causing adeno-associated virus (AAV) that has been changed to carry and deliver a gene encoding a miRNA that will recognize, bind and non-selectively lower the human huntingtin protein.”
> “The therapeutic goal is to inhibit the production of the mHTT by using AAV to deliver genes encoding miRNA directly to the brain for non-selective (both mutant and normal) lowering of the huntingtin protein.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.6.1-2"></a>

###### Non-selective huntingtin knockdown: company description of the construct

> “AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients.”

Source: [uniQure press release, FDA Fast Track designation (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-receives-fda-fast-track-designation-amt-130-gene-therapy)

<a id="topic-2.1.2.6.1-3"></a>

###### miQURE platform: degradation of disease-causing transcripts and secondary exosome-mediated silencing

> “AMT-130 is a miQURE®-based gene-transcript silencing technology designed to degrade disease-causing gene transcripts without off-target toxicity while inducing silencing throughout the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “miQURE is designed to degrade disease-causing genes without off-target toxicity and induce silencing of the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.1-4"></a>

###### Mechanistic goals of the phase I/II studies: biodistribution and durable knockdown of huntingtin and exon 1 huntingtin

> “biodistribution of the therapy in both the deep and cortical structures of the brain via transport of the AAV vector and through secondary exosome-mediated delivery”
> “safe, on-target and durable knockdown of HTT and exon 1 HTT.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.6.1-5"></a>

###### Axonal transport of the vector to other brain regions affected by the disease

> “AMT-130 is axonally transported to other brain regions affected by HD”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “These data are consistent with prior studies and further demonstrate that AAV5 undergoes anterograde and retrograde axonal transport following infusion, resulting in broad transduction of the structures affected by Huntington’s disease.”

Source: [uniQure press release, preclinical publication (2019)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publication-preclinical-data-amt-130)

<a id="topic-2.1.2.6.1-6"></a>

###### Construct attributes stated by the sponsor: suppression of huntingtin and of the exon 1 isoform

> “Suppresses both HTT and the highly toxic exon-1 isoform”
> “Precision-delivery directly to diseased areas of the brain”
> “Minimizes systemic exposure of drug”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.1.2.6.1-7"></a>

###### Construct design: targeting of huntingtin exon 1 and total silencing of both alleles

> “In the first approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1.”
> “Twenty-one miHTT variants were designed to target HTT exon 1.”
> “For the first time, we show that the therapeutic pri-miRNA scaffold influences HTT knock-down and guide strand processing in vivo.”

Source: [Miniarikova et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014463/)

<a id="topic-2.1.2.6.1-8"></a>

###### Scaffold selection and absence of passenger strand activity in vitro

> “miH12-135 was highly efficient and together with miH12-101 and miH12-451 did not produce any passenger strand.”

Source: [Miniarikova et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014463/)

<a id="topic-2.1.2.6.1-9"></a>

###### Suppression of mutant huntingtin aggregates and neuronal dysfunction in a lentiviral rat model

> “Our data demonstrated suppression of mutant HTT messenger RNA, which almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated neuronal dysfunction.”
> “Ultimately, AAV5-delivered-miRNA-mediated HTT lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic precursor sequences.”

Source: [Miniarikova et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658675/)

<a id="topic-2.1.2.6.1-10"></a>

###### Continuous microRNA expression after a single vector administration

> “Importantly, the AAV-delivered-miRNA-based gene therapy approach comprises continual expression of artificial miRNAs following a single administration of an AAV vector, resulting in long-term HTT lowering.”

Source: [Miniarikova et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5658675/)

<a id="topic-2.1.2.6.1-11"></a>

###### Rationale for lowering huntingtin messenger RNA rather than the protein

> “miRNA-based lowering strategies are designed to lower HTT mRNA levels and thereby reduce the overall mutant HTT protein.”
> “The latter is crucial for assessment of tolerability of non-selective HTT lowering, in which case the remaining levels of endogenous HTT are relevant.”

Source: [Miniarikova et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6079476/)

<a id="topic-2.1.2.6.1-12"></a>

###### Cell types transduced by AAV5 after intracranial injection

> “AAV1, AAV2, and AAV5 preferentially transduce neurons and astrocytes after intracranial injection, whereas AAV9 more efficiently transduces astrocytes after intravenous delivery.”

Source: [Miniarikova et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6079476/)

<a id="topic-2.1.2.6.1-13"></a>

###### Off-target assessment in patient-derived neurons and astrocytes

> “Small RNA sequencing showed that mature miHTT was processed correctly without off-target passenger strand.”
> “No cellular microRNAs were dysregulated, indicating that endogenous RNAi machinery was unaffected by miHTT overexpression.”
> “qPCR validation of in silico-predicted off-target transcripts, next-generation sequencing, and pathway analysis confirmed absence of dysregulated genes due to sequence homology or seed-sequence activity of miHTT.”

Source: [Keskin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6849441/)

<a id="topic-2.1.2.6.1-14"></a>

###### Non-allele-selective lowering: tolerability of wild-type huntingtin reduction in humanized mice

> “Importantly, non-selective suppression of huntingtin was generally tolerated, however high dose AAV5-miHTT did induce astrogliosis.”
> “Finally, we also observed that potent reduction of wild type HTT (wtHTT) in Hu21 control mice was tolerated up to 7 months post-injection but may induce impairment of motor coordination and striatal atrophy.”
> “Taken together, our data suggests that in the context of HD, the therapeutic benefits of mHTT reduction may outweigh the potentially detrimental effects of wtHTT loss following non-selective HTT lowering.”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.1-15"></a>

###### Non-allele-selective lowering: unknown consequences in adults stated to trial participants

> “AMT-130 lowers both normal and mutant huntingtin protein in animals. The effects of lowering normal and mutant huntingtin protein levels in adults are currently unknown.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.6.1-16"></a>

###### Extracellular vesicle-mediated spread of the therapeutic microRNA between cells

> “Preclinical studies demonstrate the brain-wide spread of AAV5-miHTT following a single intrastriatal injection, which is partly mediated by neuronal transport.”
> “Transfer of miHTT to recipient (HEK-293T, HeLa, and HD patient-derived neurons) cells was observed, which significantly reduced HTT mRNA levels.”
> “In summary, we provide evidence that an engineered miRNA”
> “is loaded into EVs, transported across extracellular space, and taken up by neighboring cells, and importantly, that miHTT is active in recipient cells downregulating HTT expression.”

Source: [Morais et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9455173/)

<a id="topic-2.1.2.6.1-17"></a>

###### Two routes of spread from the injection site: axonal transport and vesicle transport

> “(ii) The AAV is then transported to distant brain regions (e.g., the cortex) via axonal anterograde/retrograde transport.”
> “(iii) Because of its miR-451 scaffold, miHTT is actively and preferentially loaded into EVs, resulting in intercellular transport of miHTT, independently of neuronal connections, to adjacent cells.”

Source: [Morais et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9455173/)

<a id="topic-2.1.2.6.1-18"></a>

###### Exon 1 huntingtin protein as a target: N-terminal fragments and aberrant splicing

> “Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein.”
> “Consistently accumulating evidence indicates that small N-terminal fragments containing extended polyQ tracts significantly contribute mHTT cellular mislocalization, aggregation and toxicity.”
> “AMT-130 is an AAV5-delivered miRNA which is administered through a one-time intrastriatal injection.”

Source: [van der Bent et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9532260/)

<a id="topic-2.1.2.6.1-19"></a>

###### Target sequence present in both full-length and exon 1 huntingtin transcripts

> “We have developed an engineered microRNA targeting the HTT exon 1 sequence (miHTT), delivered via adeno-associated virus serotype 5 (AAV5). The target sequence of miHTT is present in both FL HTT and HTT1a transcripts.”

Source: [Sogorb-Gonzalez et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629698/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Huntingtin lowering in the striatum and cortex of humanized mice at 7 months

> “We show that intrastriatal administration of AAV5-miHTT results in potent and sustained HTT suppression for at least 7 months post-injection.”
> “In the striatum, we observed a dose-dependent reduction of wtHTT with low, medium and high dose treatments resulting in 42%, 62% and 87% suppression at 7 months post-injection, respectively”
> “Moreover, a dose-dependent reduction of wtHTT was also observed in the cortex with low, medium and high dose treatments resulting in 16%, 33% and 62% reduction at 7 months post-injection, respectively”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.2-2"></a>

###### Greater lowering at the injection site than in the cortex

> “Consistent with intrastriatal delivery of AAV5-miHTT, we observed a significantly higher magnitude of both wt and mHTT lowering in the striatum compared to the cortex at 7 months post-injection”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.2-3"></a>

###### Huntingtin lowering and aggregate suppression in Q175 knock-in mice at 12 months

> “A significant dose-dependent average reduction of mutant HTT protein of up to 39% in the striatum and up to 13% in the cortex of Q175 KI mice 12 months after intrastriatal injection of AAV5-miHTT was detected”
> “AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex.”

Source: [Spronck et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446047/)

<a id="topic-2.1.2.6.2-4"></a>

###### Motor coordination and survival in R6/2 mice after a single administration

> “AAV5-miHTT treatment showed a significant improvement in motor coordination on the rotarod by an increase in latency to fall of 22 s in the high-dose group, which is an increase of 56% compared with vehicle-treated R6/2 mice (one-way ANOVA, p = 0.0226; Figure 6B).”
> “One-time AAV5-miHTT administration resulted in a median survival improvement of over 4 weeks compared with untreated R6/2 HD mice.”

Source: [Spronck et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6446047/)

<a id="topic-2.1.2.6.2-5"></a>

###### Mutant huntingtin messenger RNA and protein lowering in transgenic minipigs

> “Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT.”
> “Consistent with the vector DNA and miHTT expression in the cortex, we also detected a significant reduction of 42.7% (SD ±25.4%; p = 0.0066) more distal in the cortex.”
> “This is the first demonstration of widespread human mutant huntingtin lowering in the large-animal model.”

Source: [Evers et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6127509/)

<a id="topic-2.1.2.6.2-6"></a>

###### Mutant huntingtin protein lowering by brain region and in cerebrospinal fluid in minipigs at 6 and 12 months

> “Expression of miHTT strongly correlated with vector DNA, with a corresponding reduction of mutant HTT (mHTT) protein of more than 75% in injected areas, and 30 to 50% lowering in distal regions.”
> “CSF miHTT expression was detected up to 12 months, with CSF mHTT protein lowering of 25 to 30% at 6 and 12 months after dosing.”

Source: [Vallès et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33827977/)

<a id="topic-2.1.2.6.2-7"></a>

###### Regional mutant huntingtin lowering reported by the sponsor at 12 months in minipigs

> “At 12 months, the most pronounced mHTT protein lowering was observed in the putamen (85%), caudate (80%) and amygdala (78%), followed by thalamus (56%) and cerebral cortex (44%).”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.2-8"></a>

###### Huntingtin messenger RNA and protein lowering in patient-derived neurons

> “One-time AAV5-miHTT treatment significantly reduced human HTT mRNA by 57% and Htt protein by 68% in neurons.”

Source: [Keskin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6849441/)

<a id="topic-2.1.2.6.2-9"></a>

###### Reduction of exon 1 huntingtin messenger RNA and protein in two mouse models

> “Intrastriatal administration of AAV5-miHTT resulted in dose-dependent expression of mature miHTT microRNA in cortical brain regions, accompanied by significant lowering of both FL HTT and HTT1a mRNA expression at 2 months postinjection.”
> “Mutant HTT and HTTexon1 protein levels were also significantly reduced in the striatum and cortex of heterozygous zQ175 knock-in mice at 2 months after AAV5-miHTT treatment and in humanized Hu128/21 mice 7 months post-treatment.”
> “These data demonstrate that, in addition to FL HTT, AAV5-miHTT also effectively reduces the highly pathogenic HTTexon1 protein in HD.”

Source: [Sogorb-Gonzalez et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629698/)

<a id="topic-2.1.2.6.2-10"></a>

###### Neurochemical and volumetric markers in homozygous Q175FDN mice

> “High dose AAV5-miHTT treatment partially rescued tNAA depletion (P = 0.0003) (Fig. 6A), and tNAA concentrations in high dose-treated animals were restored to near-wild-type levels.”
> “AAV5-miHTT partially rescues regional volume loss in brains of 6-month-old homozygous Q175FDN mice”
> “Finally, gene expression analysis by RNA sequencing revealed a distinct transcriptional phenotype associated with mutant HTT expression in the striatum that was partially rescued by high dose AAV5-miHTT.”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.2-11"></a>

###### Plasma neurofilament light chain unchanged by treatment in homozygous Q175FDN mice

> “Plasma neurofilament light was elevated in homozygous Q175FDN mice (P < 0.0001) but was unchanged by AAV5-miHTT (Supplementary Tables 22 and 23), indicating that HTT lowering in the brain does not affect peripheral abundance of neurofilament light in this model.”
> “It is also possible that plasma neurofilament light may decrease with a longer treatment duration, and that our experimental timeline was too brief to capture the full effect of AAV5-miHTT therapy on this outcome measure.”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.2-12"></a>

###### Exploratory pharmacodynamic biomarkers in the U.S. study: mutant huntingtin and neurofilament light chain in cerebrospinal fluid

| Field | Quoted record |
| --- | --- |
| Exploratory outcome measure | “CSF Mutant Protein (fM)” |
| Exploratory outcome measure | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Measure description of each | “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.6.2-13"></a>

###### Durability marker: engineered microRNA in cerebrospinal fluid extracellular vesicles up to two years in non-human primates

> “Quantifiable engineered microRNA levels enriched in extracellular vesicles were detected in the CSF up to two years after brain infusion.”
> “Altogether, these results confirm the long-term expression of adeno-associated viral vector serotype 5-delivered microRNAs and support the use of extracellular vesicle-associated microRNAs as novel translational pharmacokinetic markers in ongoing clinical trials of gene therapies for neurodegenerative diseases.”

Source: [Sogorb-Gonzalez et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8093922/)

> “After AAV treatment in non-human primates, the secretion of mature engineered microRNA molecules was confirmed, with extracellular microRNA levels correlating with viral dose and cellular microRNA expression in neurons.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Vector biodistribution after MRI-guided convection-enhanced delivery in non-human primates and rats

> “Widespread vector DNA and miHTT transgene distribution in the brain was found, particularly in areas associated with HD pathology.”
> “Analysis of both NHP and rat brain regions showed high levels of vector DNA and miHTT expression that were sustained over 6 months and were widespread throughout the brain, thereby confirming high transduction of brain regions relevant for HD and subsequent expression of the transgene in those regions.”
> “Dose-related transduction of the target structures was observed in NHP at 6 months following AAV5-miHTT administration.”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-2"></a>

###### Persistent expression and correlation of vector DNA with transgene expression

> “AAV5-miHTT achieved persistent high-level expression of vector DNA and miHTT transgene.”
> “Even though miHTT expression did not show a strong dose-dependent effect in the high dose, there was a strong correlation between brain vector DNA and miHTT transgene expression (r = 0.68, p < 0.0001) (Figure 3d).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-3"></a>

###### Vector DNA in cerebrospinal fluid and blood immediately after administration

> “The levels of vector DNA in the CSF in all AAV5-miHTT-treated NHP were approximately 1 × 1010 gc/mL at 1-h post injection.”
> “These data show that after intrastriatal delivery of AAV5-miHTT the vector is shed into CSF and blood very rapidly, which indicated that initially the vector was able to spread systemically and was not limited to the CNS.”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-4"></a>

###### Shedding of vector DNA in body fluids and feces and its decline by three months

> “One week after dosing, vector DNA was found in blood, plasma, feces, urine, nasal swabs and saliva.”
> “These levels declined at 1 month after dosing and by 3 months after dosing the vector DNA levels were below the limit of detection for plasma, feces, urine and semen.”
> “In feces, urine and semen vector DNA was found at day 7 and 1 months after dosing, but no vector was present after 3 months (data not shown).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-5"></a>

###### Neutralizing antibodies to the vector capsid six months after dosing

> “As would be expected, NAb to AAV5 were present in the blood plasma of both NHP and rats treated with AAV5-miHTT 6 months after dosing (data not shown).”

Source: [Spronck et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908995/)

<a id="topic-2.1.2.6.3-6"></a>

###### Dose-dependent vector distribution in the transgenic minipig brain

> “We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression.”
> “Although both doses of AAV5-miHTT resulted in a local transduction and subsequently HTT mRNA and huntingtin protein lowering, the highest dose of AAV5-miHTT resulted in vector DNA and miHTT expression in the cortex, suggesting a dose-dependent viral transport.”

Source: [Evers et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6127509/)

<a id="topic-2.1.2.6.3-7"></a>

###### Vector DNA distribution and persistence at 6 and 12 months in minipigs after striatal delivery

> “rAAV5-miHTT (1.2 × 1013 vector genome (VG) copies per brain) was successfully administered into the striatum (bilaterally in caudate and putamen), using age-matched untreated animals as controls.”
> “Widespread brain biodistribution of vector DNA was observed, with the highest concentration in target (striatal) regions, thalamus, and cortical regions.”
> “Vector DNA presence and transgene expression were similar at 6 and 12 months after administration.”

Source: [Vallès et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33827977/)

<a id="topic-2.1.2.6.3-8"></a>

###### Extent of brain coverage reported by the sponsor in minipigs

> “Vector DNA distribution and transgene expression in minipig brains demonstrated extensive brain coverage comparable at the interim sacrifice timepoints of 6- and 12-months post administration, leading to significant lowering of mutant huntingtin (mHTT) protein in the brain.”
> “The results confirm the long-term expression (up to two years) of AAV5-delivered microRNAs in non-human primates and provide further support for the potential use of extracellular vesicle-associated microRNAs as novel biomarkers in ongoing clinical trials of gene therapies for neurodegenerative diseases, including AMT-130.”

Source: [uniQure press release, preclinical publications (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-publications-preclinical-data-amt-130)

<a id="topic-2.1.2.6.3-9"></a>

###### Vector DNA in striatum, cortex, and cerebellum after striatal injection in mice

> “AAV5 vector DNA was present in a dose-dependent pattern in (A) striatum (P < 0.0001) and (B) cortex (P = 0.0009), and detectable in high dose-treated animals in (C) cerebellum (P = 0.0326).”
> “In striatum (the region of direct AAV5-miHTT injection), AAV5 vector DNA was detected in a dose-dependent pattern (P < 0.0001), with 9.6 × 105 and 4.3 × 107 AAV5 genome copies per μg total DNA measured in low and high dose-treated mice, respectively (Fig. 2A).”

Source: [Thomson et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232253/)

<a id="topic-2.1.2.6.3-10"></a>

###### Distribution to the hippocampus and cortex and transduction of neurons, astrocytes, and microglia

> “AAV5-GFP showed broad distribution at all time points evaluated and could clearly be observed in the striatum (site of injection), the hippocampus and deeper layers of the cortex at 7 months post-injection (Figure 2A).”
> “We qualitatively observed co-localization of GFP with NeuN (Figure 2B), DARPP-32 (Figure 2C), GFAP (Figure 2D) and Iba1 (Figure 2E) demonstrating transduction of neurons, striatal medium spiny neurons, astrocytes and microglia, respectively.”

Source: [Caron et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7145682/)

<a id="topic-2.1.2.6.3-11"></a>

###### Persistence in the brain and vector shedding as registry outcome measures

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Duration of persistence of AMT-130 in the brain” | “Change over time in levels of AMT-130-derived Vector DNA Expression in the Cerebrospinal Fluid (CSF)” | “Collected for duration of study through month 72 (Cohorts 1 & 2) and through month 16 (Cohorts 3 & 4)” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “- Change over time in AAV5 vector shedding”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pediatric use: UK paediatric investigation plan waiver granted in all age groups

> “Granting a waiver in all age groups for the listed condition(s)”
> “All subsets of the paediatric population from birth to less than 18 years of age”
> “Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.”

Source: [MHRA paediatric investigation plan waiver decision (2026)](https://cms.mhra.gov.uk//system/files/2026-07/mhra-102322-pip01-26.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Age range of the population studied in the European phase Ib/II study

> “Male and female participants 25-65 years of age.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.8-3"></a>

###### Pregnancy and breastfeeding: excluded, with contraception required of participants

> “All female participants of childbearing potential (FOCP) must have a negative serum pregnancy test at Screening, (and Visit 1A, as appropriate), a negative pregnancy urine dipstick at Baseline, and not be breastfeeding. All FOCPs and sexually mature males must be compliant with a highly effective birth control method.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic and renal laboratory limits applied at screening

> “Alanine aminotransferase (ALT) >2 × upper limit of normal (ULN)”
> “Total bilirubin >2 × ULN”
> “Creatinine >1.5 × ULN”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.8-5"></a>

###### Juvenile Huntington's disease

No evidence found.

<a id="topic-2.1.2.8-6"></a>

###### Dosing in hepatic impairment, renal impairment, or older adults

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Ifezuntirgene inilparvovec

<a id="topic-2.1.2.9.1-1"></a>

###### Concomitant medications that could affect the ability to undergo the neurosurgical procedure

> “Current or recurrent disease, (including pre-existing cardiovascular or pulmonary conditions) infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a participant's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.9.1-2"></a>

###### Coagulation and platelet thresholds required before administration

> “Platelet count <100,000/mm3”
> “Prothrombin time (PT) >1.2 × ULN”
> “Partial thromboplastin time (PTT) >1.2 × ULN”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.9.1-3"></a>

###### Prior experimental agents, gene therapy, and huntingtin-lowering strategies

> “Please note that participants will need to be off any other experimental agents for 60 days prior to screening. Previous exposure to gene therapy, huntingtin lowering strategies, or experimental brain surgery are prohibitive to study participation.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Ifezuntirgene inilparvovec on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dose supporting the marketing applications: 36-month data from high-dose participants

> “The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.10.1-2"></a>

###### Single administration: one dose given during a neurosurgical visit

> “It is important to reiterate that AMT-130 is administered only once.”
> “AMT-130 is administered once by neurosurgical procedure.”
> “This investigational treatment is the first one-time administered gene therapy to enter clinical testing for the treatment of HD.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

> “AMT-130 is administered one time with potentially long-term effects.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

<a id="topic-2.1.2.10.1-3"></a>

###### Infusion volume and concentration of the clinical dose

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Administration: single MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen

> “Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.10.2-2"></a>

###### Number of infusions per hemisphere

> “3 infusions per hemisphere”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Burr holes and micro-catheter placement under general anesthesia

> “This is done by drilling two to six small holes in the skull and administering AMT-130 by a micro-catheter.”
> “AMT-130 is delivered directly to the brain and will include risks associated with general anesthesia and micro-catheter placement in the brain.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.10.2-4"></a>

###### Procedure duration stated in the eligibility criteria of the European study

> “Current or recurrent disease (including pre-existing cardiovascular or pulmonary conditions), infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a participant's safety or their ability to undergo a neurosurgical procedure (10+ hour surgical procedure) or comply with the procedures and study visit schedule.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.10.2-5"></a>

###### Delivery method described in a review of neurosurgical therapies for Huntington's disease

> “In clinical trials, a current Phase 1/2 study funded by UniQure Biopharma includes patients with early manifestations of HD (ages 25–65 years) and uses bilateral striatal injection of AAV5-mHTT using an MRI-guided convection-enhanced delivery method and sham surgery for the randomized control arm”
> “Although technically possible, manual infusion does not offer the control and consistency of more advanced techniques”
> “namely MRI-guided convection-based delivery using a pressure gradient generated by a pump.”
> “Stereotactic neurosurgical techniques will be critical in optimizing therapeutic efficacy through safe, reproducible treatment delivery.”

Source: [Kim et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585891/)

<a id="topic-2.1.2.10.2-6"></a>

###### Convection-enhanced delivery: method and the role of real-time imaging

> “CED, on the other hand, uses a pressure gradient generated by an automated pump to distribute high concentrations of macromolecules over significant volumes within the brain parenchyma by fluid convection, allowing for measurable, consistent and predictable infusion rates.”
> “One major challenge has been the lack of real-time visualisation of vector delivery, without which it is difficult to improve the distribution of vector during infusions.”
> “This new paradigm allows visualisation of the accuracy and adequacy of viral vector delivery within target structures, enabling intertrial modifications in surgical approaches, cannula design, vector volumes and dosing.”

Source: [Richardson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569395/)

<a id="topic-2.1.2.10.2-7"></a>

###### Cannula design and backflow during intraparenchymal infusion

> “Features of the design of the infusion cannula for CED can profoundly impact successful delivery of gene therapy.”
> “Combined with increased infusion flow rates, these modifications resulted in greatly improved target coverage when evaluated in NHPs.”

Source: [Richardson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7569395/)

<a id="topic-2.1.2.10.2-8"></a>

###### Administration of the approved intraputaminal gene therapy eladocagene exuparvovec: setting and infusion parameters

> “KEBILIDI should be administered in a medical center which specializes in stereotactic”
> “KEBILIDI is administered as four intraputaminal infusions in a single stereotactic neurosurgical”
> “Administer KEBILIDI only using an FDA-authorized cannula for intraparenchymal”
> “KEBILIDI is intended to be administered with an infusion pump capable of infusing at a”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

| Field | Quoted record |
| --- | --- |
| Total recommended dose | “1.8x1011 vg (0.32 mL)” |
| Volume (dose) per infusion | “0.08 mL (0.45x1011 vg)” |
| Location of infusions | “2 in anterior putamen, 2 in posterior putamen” |
| Infusion rate at each target point | “0.003 mL/min” |
| Dose duration for infusion at each target point | “27 minutes” |

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Current access: clinical trials only; no expanded access

> “After careful consideration, uniQure has decided not to provide expanded access to any of our investigational gene therapies at this time.”
> “Delivery and administration of the investigational therapy outside of the clinical trial setting must be feasible, including ensuring that there are appropriate healthcare facilities available to administer the investigational therapy, manage potential side effects, and ensure ongoing follow-up as needed.”

Source: [uniQure expanded access policy (2024)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/uniQure_Expanded-Access-Policy_05June24.pdf)

<a id="topic-2.1.2.11-2"></a>

###### Commercial build-out: field medical, market access, and strategic account teams

> “The Company continues to advance its launch readiness activities, including the build out of its field medical, market access, and strategic account teams as well as engagement with U.S. Huntington’s disease treatment centers.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.11-3"></a>

###### Treatment centers: HDSA Centers of Excellence and stereotactic surgical infrastructure

> “Established HDSA COEs and surgical infrastructure are well positioned to serve HD patients, with ongoing efforts to prioritize key treatment centers for launch”
> “Heat Map of Clearpoint Neuro Capable Facilities and HDSA COEs by Patient Volume”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.1.2.11-4"></a>

###### Neurosurgical administration requirements

> “AMT-130 is administered via a standard stereotactic procedure that can be broadly performed.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

> “Moreover, certain of our delivery modalities, such as direct delivery of product candidates to the brain, may require significant time and physician ability and skill.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “AMT-130 was infused into two specific brain regions (caudate and putamen, together known as the striatum) under general anesthesia at a surgical center that specializes in these procedures.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.11-5"></a>

###### Manufacturing supply through Genezen

> “Following the Lexington Transaction, Genezen may experience challenges in adapting the Lexington Facility to meet the manufacturing and supply needs for products other than HEMGENIX as a result of capacity and resource constraints, or its inability to adapt to new manufacturing processes, among other challenges.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “This transaction achieves these objectives by unlocking significant cost savings while maintaining preferential access to world-class gene therapy manufacturing.”

Source: [uniQure press release, sale of manufacturing facility to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-sale-commercial-manufacturing-facility-genezen)

<a id="topic-2.1.2.11-6"></a>

###### Specialty distribution, risk evaluation and mitigation strategy, and payer coverage

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Background Huntington's disease medications: stable for 3 months before screening

> “All HD concomitant medications (addressing motor, behavioral, and cognitive symptoms) must be stable for 3 months prior to Screening with no change in clinical symptoms requiring change in medication prior to anticipated administration procedure”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “All HD concomitant medications (addressing motor, behavioral and cognitive symptoms) must be stable for 3 months prior to Screening with no change in clinical symptoms requiring change in medication prior to anticipated administration procedure.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.12-2"></a>

###### Excluded prior and concurrent therapies

> “Receipt of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study.”
> “Participation in an investigational trial or investigational paradigm (such as exercise/physical activity, cognitive therapy, brain stimulation) within 60 days prior to Screening or anytime over the duration of this study.”
> “Any history of gene therapy, RNA or DNA targeted HD specific investigational agents, such as antisense oligonucleotides (ASOs), cell transplantation or any other experimental brain surgery.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Patients may be ineligible to receive another gene therapy treatment after receiving AMT-130.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.12-3"></a>

###### Immunosuppression regimen specified in the protocols

> “Known allergy, sensitivity, or other contraindication to medications in the immunosuppression regimen in this protocol.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Known immunocompromised status including participants who have undergone organ transplantation or who test positive at Screening for the human immunodeficiency virus (HIV); or who are at risk of pathogen reactivation if immunosuppressed, including participants who test positive at screening for hepatitis C virus antibody (anti-HCV), hepatitis C virus ribonucleic acid (HCV RNA), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); or who have history of active tuberculosis or a positive tuberculosis blood test during screening.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.12-4"></a>

###### Immunosuppression at the discretion of the treating physician, October 2022

> “The DSMB also made no change to the treatment protocol regarding the use of immunosuppression that will continue to be at the discretion of the treating physician.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-2.1.2.12-5"></a>

###### Perioperative immunosuppression and steroids given with administration, 2023

> “All four crossover patients (3 high dose, 1 low dose) received a short course of immunosuppression therapy concurrent with the administration of AMT-130.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

> “Additionally, six high-dose patients have received perioperative steroids with the administration of AMT-130 to reduce the risk of inflammation.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

> “In 2023, we initiated patient dosing in a third cohort consisting of up to 12 patients to further investigate both doses of AMT-130 together with perioperative immunosuppression using the current, established stereotactic administration procedure.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.12-6"></a>

###### Prophylactic short-term steroid regimen, May 2025

> “The Company expects a short-term steroid regimen will be incorporated as a prophylactic immunosuppression strategy.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

> “In February 2025, we completed enrollment in a third cohort investigating an optimized immunosuppression regimen.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.12-7"></a>

###### Agents, doses, and duration of the immunosuppression regimen

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Ifezuntirgene inilparvovec on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### AAN movement disorders quality measurement sets: conditions covered

> “Find measures to improve care for your patients diagnosed with a movement disorder.”
> “Parkinson's disease (2020)”
> “Essential tremor (2016)”

Source: [American Academy of Neurology movement disorders quality measures](https://www.aan.com/practice/movement-disorders-quality-measures)

<a id="topic-2.1.2.13-2"></a>

###### Ifezuntirgene inilparvovec-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Tetrabenazine: indication, boxed warning monitoring, and individualized oral dosing

> “XENAZINE is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.”
> “Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy.”
> “The chronic daily dose of XENAZINE used to treat chorea associated with Huntington’s disease (HD) is determined individually for each patient.”
> “Patients who require doses of XENAZINE greater than 50 mg per day should be first tested and genotyped to determine if they are poor metabolizers (PMs) or extensive metabolizers (EMs) by their ability to express the drug metabolizing enzyme, CYP2D6.”
> “Re-emergence of chorea may occur within 12 to 18 hours after the last dose of XENAZINE”

Source: [Xenazine prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Deutetrabenazine: indication, boxed warning monitoring, and oral dosing

> “AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of:”
> “Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior.”
> “Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, and tolerability, up to a maximum recommended daily dosage of 48 mg”
> “Administer AUSTEDO XR with or without food in once-daily doses”
> “Maximum recommended dosage of AUSTEDO XR or AUSTEDO in poor CYP2D6 metabolizers is 36 mg per day”

Source: [Austedo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208082s018,216354s008lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Valbenazine: indication, boxed warning monitoring, and oral dosing

> “INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with:”
> “Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior.”
> “Chorea associated with Huntington’s disease: The initial dosage is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily.”
> “Administer INGREZZA and INGREZZA SPRINKLE orally with or without food”

Source: [Ingrezza prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209241Orig1s034lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine

> “Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).”

Source: [Claassen et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5331691/)

<a id="topic-2.1.2.14-5"></a>

###### Approved VMAT2 inhibitors: GRADE-based indirect comparison

> “There is low-quality evidence that tetrabenazine and deutetrabenazine do not differ in efficacy or safety.”

Source: [Rodrigues et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573977/)

<a id="topic-2.1.2.14-6"></a>

###### Symptomatic antichoreic agents: open-label randomized comparison of tetrabenazine, tiapride, and olanzapine

> “We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.”
> “Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.”

Source: [Youssov et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41014964/)

<a id="topic-2.1.2.14-7"></a>

###### Route of administration compared with antisense oligonucleotides and gene therapy

> “Unlike earlier approaches such as antisense oligonucleotides ( ASOs) given by spinal tap, or virus-based gene therapies delivered by brain surgery, SKY-0515 is a small-molecule compound which can be taken by mouth and can spread throughout the body. This is very similar to votoplam, another splice modulator in development for HD by Novartis and PTC Therapeutics.”

Source: [Harding (2026)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)

<a id="topic-2.1.2.14-8"></a>

###### HTT lowering targets in other trials: independent commentary

> “Astute readers may notice that 70% lowering is a fair bit higher than the current target in other HTT lowering trials of around 50%. Currently, most companies have targeted the 30-50% range for HTT lowering drugs.”

Source: [Hernandez (2024)](https://en.hdbuzz.net/373/)

<a id="topic-2.1.2.14-9"></a>

###### Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design

| Trial | Intervention | Mechanism of action | Population | Comparison | Study design | Estimated enrolment |
| --- | --- | --- | --- | --- | --- | --- |
| INVEST-HD (NCT07326709) | “Votoplam” | “Small molecule splicing modulator” | “Early HD (CAG ≥40, UHDRS TFC=13, TMS 7-25, IS ≥90” | “Placebo” | “Randomized, double-blind, placebo-controlled, parallel-group (phase III)” | “770” |
| FALCON-HD (NCT07378644) | “SKY-0515” | “mRNA splicing modulator designed to lower mHTT and PMS1” | “Early HD; UHDRS TFC ≥10, TMS ≥6, IS ≥70” | “Placebo” | “Randomized, double-blind, placebo-controlled, dose-ranging, parallel-group (phase II/III)” | “400” |
| NCT06826612 | “Intraparenchymal infusion of SPK-10001 into caudate and putamen bilaterally” | “AAV-mediated gene therapy delivering therapeutic construct to striatum to modify disease progression” | “HD-ISS stage 1 or 2 HD; UHDRS TFC ≥11” | “Placebo/sham surgery” | “Randomized, sequential dose-escalation, quadruple-masked, parallel assignment” | “53” |
| NCT06585449 | “ALN-HTT02” | “RNA interference selectively targeting exon 1 of HTT mRNA” | “HD-ISS stage 2 or early stage 3 HD” | “Placebo” | “Randomized, double-blind, parallel assignment, single dose” | “54” |
| POINT-HD (NCT07246941) | “RG6496” | “Intrathecally administered HTT-lowering therapy; SNP-targeted approach” | “HD gene-expansion carrierss with target SNP, CAG >39, UHDRS TFC ≥10, TMS ≥6, IS ≥70” | “Placebo” | “Randomized, placebo-controlled, single-ascending-dose study with open-label extension (phase I)” | “40” |
| VO659-CT01 (NCT05822908) | “Intrathecal administration of VO659” | “ASO targeting mutant HTT and ataxin RNA to reduce toxic protein levels” | “SCA1, SCA3, HD” | “None” | “Open-label, non-randomized” | “68” |
| NCT07344519 | “ER2001” | “Small interfering RNA” | “Adults with early manifest HD who completed study ER2001-001” | “None” | “Open-label, dose-escalation, single-group (phase I)” | “8” |
| GENERATION HD2 (NCT05686551) | “Tominersen” | “Non-allele-selective ASO” | “Prodromal and early HD” | “Placebo” | “Randomized, double-blind, dose-finding trial” | “360” |
| SELECT-HD (NCT05032196) | “WVE-003” | “Allele-selective ASO” | “Early HD” | “Placebo” | “Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial” | “36” |
| PRECISE-HD (NCT07609108) | “Pridopidine” | “Sigma-1 receptor activation” | “Manifest HD (not receiving antidopaminergic medications for ≥6 months before screening)” | “Placebo” | “Randomized, double-blind, placebo-controlled, parallel-group trial with 52-week treatment period followed by a 2-year open-label extension (phase III)” | “400” |

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

> “New trials added since the last Clinical Trials Update are indicated by *. Pharmacological trials terminated are indicated by †.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-10"></a>

###### Delivery routes under investigation: subcutaneous SRP-1005 as an alternative to intrathecal or neurosurgical administration

> “SRP-1005 is designed to reduce HTT expression following subcutaneous administration through a transferrin receptor 1 -mediated delivery platform intended to facilitate central nervous system (CNS) penetration.”
> “The programme is noteworthy for its systemic subcutaneous delivery approach, which, if successful, could provide an alternative to intrathecal or neurosurgical administration strategies currently being investigated for HTT-lowering therapies.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-11"></a>

###### Votoplam: oral splicing modifier, 24-month extension versus natural history

> “In the interim analysis following 24 months of votoplam treatment, there was evidence of dose-dependent benefit in slowing progression on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) relative to a propensity weighted natural history cohort in Stage 2 participants, with 52% and 28% slowing for 10 mg and 5 mg participants, respectively.”
> “Votoplam (formerly PTC518) is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels.”

Source: [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)

<a id="topic-2.1.2.14-12"></a>

###### Votoplam: route and 12-week PIVOT-HD primary endpoint

> “PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.”
> “The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-13"></a>

###### Votoplam: phase 3 INVEST-HD design

> “INVEST-HD is a randomised, placebo-controlled, double-blind, phase III interventional study designed to evaluate whether votoplam slows disease progression in participants with early symptomatic HD compared with placebo.”
> “Votoplam, also referred to as HTT227 (and formerly known as PTC518), is an orally administered small-molecule HTT-lowering therapy now being developed by Novartis for HD.”
> “Participants are randomised in a 3:2 ratio to oral votoplam or placebo, with a variable double-blind treatment duration of up to 36 months, followed by a safety follow-up visit for participants not entering a separate open-label extension.”
> “The estimated enrolment is 770 participants.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-14"></a>

###### SKY-0515 in relation to huntingtin-only lowering: independent trials review

> “SKY-0515 is designed to reduce both HTT and PMS1 proteins, the latter implicated in somatic CAG repeat expansion, a mechanistic process increasingly recognised as a key driver of neuronal loss in HD.”
> “This important phase II/III clinical trial of SKY-0515 will assess whether HTT and PMS1 lowering can offer greater therapeutic benefit than HTT reduction alone in early-stage HD.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-15"></a>

###### SKY-0515: twelve-month data compared with natural history and phase II/III FALCON-HD

> “As previously featured in the October 2025 update, 13 Skyhawk Therapeutics has reported new interim data from the ongoing phase I/II study of SKY-0515.”
> “Treated participants demonstrated positive mean changes from baseline in cUHDRS scores over 12 months, compared with an expected decline derived from propensity-weighted analyses of Enroll-HD and TRACK-HD natural-history datasets.”
> “Skyhawk also announced completion of enrolment in the Australia and New Zealand component of the phase II/III FALCON-HD programme (004-ANZ), with 144 participants enrolled ahead of schedule, and expansion of the global FALCON-HD study (NCT07378644) 41 to eight countries.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-16"></a>

###### External natural-history comparisons across HTT-lowering trials

> “Astute HDBuzz readers will have noticed that this is a similar type of comparison that was made for the AMT-130 clinical trial data which was contentious among some HD researchers.”

Source: [Harding (2026)](https://en.hdbuzz.net/phase-1-results-announced-for-skyhawks-drug-sky-0515/)

<a id="topic-2.1.2.14-17"></a>

###### Tominersen: phase 3 GENERATION HD1 dosing discontinued

> “The iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants.”
> “Study participants were randomised to either 120 mg every-2-months or 120 mg every-4-months intrathecal injections of tominersen, or placebo. The study has recruited 791 participants from 18 countries around the world.”

Source: [Roche (2021)](https://www.roche.com/media/releases/med-cor-2021-03-22b)

<a id="topic-2.1.2.14-18"></a>

###### Tominersen: GENERATION HD1 design and primary end points

> “in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo”
> “The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.”
> “Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-19"></a>

###### Tominersen: GENERATION HD1 ad hoc week 69 results with the every-16-week regimen

> “In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)”
> “Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-20"></a>

###### Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses

> “The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume”
> “The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy”
> “A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component”
> “More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group”
> “The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy”
> “this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="topic-2.1.2.14-21"></a>

###### Tominersen: GENERATION HD2 discontinued, July 2026

> “On 9th July 2026, Roche announced the discontinuation of the GENERATION HD2 (NCT05686551) 22 study of tominersen in people with prodromal and early Huntington's disease.”
> “GENERATION HD2 confirms that sustained lowering of mHTT in humans, even if it lowers wild-type as well, and does not target HTT exon 1, is associated with robust NfL lowering - often taken as indicating reduced rates of neuroaxonal damage - but that clinical benefits, if they are to emerge, may take longer than 16 months.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-22"></a>

###### Tominersen: phase 2 GENERATION HD2 unblinding anticipated in late 2026, November 2025, superseded in July 2026

> “GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.”
> “The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-23"></a>

###### RG6496: allele-selective intrathecal antisense oligonucleotide, POINT-HD terminated

> “RG6496 is a selective ASO designed to lower mHTT protein while largely preserving expression of the wild-type protein.”
> “It is administered intrathecally and achieves allele selectivity by targeting a single nucleotide polymorphism (SNP) present on the expanded huntingtin gene (HTT) allele.”
> “POINT-HD was terminated following new findings from a longer-term non-clinical study indicating that RG6496 could not be administered chronically with repeated dosing.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-24"></a>

###### Pridopidine: phase 3 PROOF-HD and EMA opinion

> “The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.”

Source: [Reilmann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618238/)

> “Prilenia and Ferrer announced that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended refusal of marketing authorisation for pridopidine in HD.”

Source: [Farag et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12847458/)

<a id="topic-2.1.2.14-25"></a>

###### Pridopidine: phase III PRECISE-HD in people not receiving antidopaminergic medications

> “PRECISE-HD is a randomised, placebo-controlled, double-blind, phase III interventional study evaluating pridopidine 45 mg twice daily in adults with HD who have not used anti-dopaminergic medications for at least six months before screening.”
> “The primary outcome measure is change from baseline to week 52 in cUHDRS score.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.1.2.14-26"></a>

###### Approved AAV gene therapy: Kebilidi indication under accelerated approval

> “KEBILIDI is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

> “This indication is approved under accelerated approval based on the change from baseline in”
> “gross motor milestone achievement at 48 weeks post-treatment”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

<a id="topic-2.1.2.14-27"></a>

###### Kebilidi: accelerated approval on a single-arm study compared with an external natural history cohort

> “Specifically, a single-arm pivotal clinical study (n=13) and an external control natural history cohort comprised the adequate and well controlled investigation.”
> “The review team recommends accelerated approval of KEBILIDI based on an intermediate clinical endpoint of motor milestone achievement at Week 48 compared to an untreated natural history cohort.”
> “The Applicant submitted cross-sectional data from an external cohort of 44 untreated patients with severe AADCD as a comparator group.”
> “In comparison, none of the 44 untreated patients had documented motor milestone achievement at last assessment.”
> “These pharmacodynamic effects on AADC disease-specific biomarkers reflect a direct treatment effect of the product on the molecular pathway of the disease and provide strong confirmatory evidence of effectiveness.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.1.2.14-28"></a>

###### Kebilidi: confirmatory evidence required for continued approval

> “Continued approval for this indication is contingent upon verification of the long-term clinical benefit in a confirmatory study.”
> “As such, the review team recommends accelerated approval based on gross motor milestone achievement at Week 48 with a post-marketing requirement to provide longer-term efficacy data to verify and describe the clinical benefit as well as demonstrate durability of the efficacy of KEBILIDI in patients with AADCD.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.1.2.14-29"></a>

###### Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: progressive motor, cognitive, and psychiatric disorder

> “Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric manifestations.”
> “HD is inherited in an autosomal dominant manner. Offspring of an individual with a heterozygous CAG repeat expansion in HTT have a 50% chance of inheriting a CAG repeat expansion.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.1-2"></a>

###### Etiology: expanded CAG repeat in HTT encoding a polyglutamine tract

> “The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.”

Source: [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)

> “Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties.”

Source: [Walker (2007)](https://pubmed.ncbi.nlm.nih.gov/17240289/)

<a id="topic-2.2.1.1-3"></a>

###### CAG repeat length thresholds

| Allele category | CAG repeat length |
| --- | --- |
| Normal alleles | “26 or fewer CAG repeats” |
| Intermediate alleles | “27 to 35 CAG repeats” |
| Reduced-penetrance HD-causing alleles | “36 to 39 CAG repeats” |
| Full-penetrance HD-causing alleles | “40 or more CAG repeats” |

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.1-4"></a>

###### Reduced penetrance of 36 to 39 CAG repeat alleles

> “Variable penetrance for alleles carrying 36-39 repeats has been noted, but the disease appears fully penetrant when the repeat numbers are >40.”

Source: [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)

> “A total of 18 of 7,315 individuals had ≥36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%).”
> “The infrequent diagnosis of HD at this CAG length is likely due to low penetrance.”

Source: [Kay et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955276/)

<a id="topic-2.2.1.1-5"></a>

###### CAG repeat length and age of onset

> “A significant inverse correlation exists between the number of HTT CAG repeats and the age of onset of HD”
> “On average, CAG repeat length accounts for up to 70% of the variability in age of onset, with an estimated 10%-20% of the residual variability being accounted for by heritable factors”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “For example, our model predicts a 91% chance that a 40-year-old individual with 42 repeats will have onset by the age of 65, with a 95% confidence interval from 90 to 93%.”

Source: [Langbehn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15025718/)

<a id="topic-2.2.1.1-6"></a>

###### Juvenile Huntington's disease and anticipation

> “Juvenile HD is rare and historically defined as HD with an onset of symptoms before age 20 years”
> “The proportion of individuals with juvenile HD varies from 1% to 15% of individuals diagnosed with HD”
> “Large expansions (i.e., an increase in allele size of >7 CAG repeats) occur almost exclusively through paternal transmission.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “HTT CAG repeat length in individuals with juvenile HD is usually >55 CAG repeats and is often caused by anticipation, usually via paternal transmission”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Huntington's disease

<a id="topic-2.2.1.2.1-1"></a>

###### Global incidence: updated systematic review and meta-analysis, 2010 to 2022

> “A total of 33 studies published between 2010 and 2022 were included. Pooled incidence was 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63). Subgroup analysis by continent demonstrated a significantly higher incidence of HD in Europe and North America than in Asia.”

Source: [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)

<a id="topic-2.2.1.2.1-2"></a>

###### Global incidence: systematic review and meta-analysis, 1985 to 2010

> “Meta-analysis of data from four incidence studies revealed an incidence of 0.38 per 100,000 per year (95% confidence interval [CI]: 0.16, 0.94). Lower incidence was reported in the Asian studies (n = 2), compared to the studies performed in Europe, North America, and Australia (n = 6).”

Source: [Pringsheim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22692795/)

<a id="topic-2.2.1.2.1-3"></a>

###### United States incidence: commercial insurance claims, 2003 to 2016

> “Using an insurance database of over 67 million enrollees, we retrospectively identified a cohort of 3,707 individuals diagnosed with Huntington’s disease between 2003–2016.”
> “We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons and a cumulative incidence rate of 1.22 per 100,000 person years.”

Source: [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)

<a id="topic-2.2.1.2.1-4"></a>

###### United States incidence: Medicare beneficiaries aged 65 years or older

> “In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years.”

Source: [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/)

<a id="topic-2.2.1.2.1-5"></a>

###### United Kingdom incidence: primary care records

> “The data showed that the incidence of HD has remained constant between 1990 and 2010 with an overall rate of 7.2 (95% CI 6.5 to 7.9) per million person-years. The systematic review identified 14 independent estimates of incidence with substantial heterogeneity and consistently lower rates reported in studies from East Asia compared with those from Australia, North America and some--though not all--those from Europe.”

Source: [Wexler et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769413/)

> “There were 586 incident cases of HD from a total at‐risk population of 10,756,901 persons (corresponding to 80,048,926 PY) during the study period (Table 1). There was no evidence that incidence increased over time (β = 0.004, p = 0.4), with 16–44 newly diagnosed cases per year identified. In 2018, incidence of HD was 0.8 (0.5–1.19) per 100,000 PY.”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Huntington's disease

<a id="topic-2.2.1.2.2-1"></a>

###### Diagnosed prevalence by Shoulson-Fahn stage: share in stages 1 and 2

> “The model estimates that in 2020, there were 66,787 individuals diagnosed with HD in the 8 included countries, of whom 62-63% were in Shoulson-Fahn stages 1 and 2 (with less severely limited functional capacity than those in stages 3-5).”
> “Data on staging distribution at diagnosis, progression, and mortality were derived from Enroll-HD.”

Source: [Crowell et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34350853/)

<a id="topic-2.2.1.2.2-2"></a>

###### Sponsor statement: people with Huntington's disease in the United States, European Union, and United Kingdom

> “Approximately 75,000 people have Huntington’s disease in the U.S., European Union (“EU”), and United Kingdom (“UK”), with approximately 40,000 symptomatic Huntington’s disease patients in the U.S.”
> “In addition to this, there are hundreds of thousands of others at risk of inheriting the disease.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### Sponsor estimate of the U.S. population treatable at launch

> “Large anticipated total addressable US market at time of launch, with potential for further growth”
> “Sources: Fisher et al. 2014, Yohrling et al. 2020, *Management Estimate.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

| U.S. population segment | Sponsor estimate |
| --- | --- |
| Initial treatable patients at launch (management estimate) | “~6,000” |
| Diagnosed HD | “~20,000 patients” |
| Symptomatic HD | “~40,000 patients” |
| Genetically identifiable HD | “~100,000 patients” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.2.1.2.2-4"></a>

###### Sponsor risk disclosure: addressable population may be smaller than projected

> “The affected populations for our gene therapies may be smaller than we or third parties currently project, which may affect the size of our addressable markets.”
> “The total addressable market opportunities for these therapies will depend upon many factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient consent, patient access and product pricing and reimbursement, among other factors.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.1.2.2-5"></a>

###### Global prevalence: updated systematic review and meta-analysis

> “Pooled prevalence was 4.88 per 100,000 (95% CI, 3.38-7.06). Subanalyses by continent demonstrated that the prevalence of HD was significantly higher in Europe and North America than in Africa.”

Source: [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)

<a id="topic-2.2.1.2.2-6"></a>

###### Global prevalence: systematic review and meta-analysis, by region

> “The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61).”

Source: [Pringsheim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22692795/)

<a id="topic-2.2.1.2.2-7"></a>

###### Geographic variation and prevalence trends

> “The prevalence of HD varies more than tenfold between different geographical regions.”
> “There was evidence of an increasing prevalence of between 15 and 20% per decade in studies from Australia, North America and Western Europe.”

Source: [Rawlins et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26824438/)

> “In populations of European ancestry, HD occurs at an average prevalence of 9.71:100,000 [Rawlins et al 2016], with up to 17:100,000 when multiple sources of ascertainment are accounted”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.2.2-8"></a>

###### United States: symptomatic and at-risk population

> “Today, there are approximately 41,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.”

Source: [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)

> “as many as ~40,000 people may have manifest HD in the US.”
> “Sources frequently state that 30,000 individuals living in the US have HD, but the methodology used to derive this prevalence estimate is unclear.”

Source: [Yohrling et al. (2019)](https://medically.gene.com/content/dam/pdmahub/restricted/neurology/hsg-2019/HSG-2019-poster-yohrling-prevalence-of-huntington-s-disease-in-the-US.pdf)

<a id="topic-2.2.1.2.2-9"></a>

###### United States: claims-based prevalence

> “In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.”

Source: [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/)

> “We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons”

Source: [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)

<a id="topic-2.2.1.2.2-10"></a>

###### United Kingdom: primary care prevalence

> “The estimated prevalence (expressed per 100 000 population) rose from 5.4 (95% CI 3.8 to 7.5) in 1990 to 12.3 (95% CI 11.2 to 13.5) in 2010.”

Source: [Evans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786631/)

> “Annual prevalence steadily increased throughout the study period, with prevalence estimates ranging from 4.3 cases (3.6–5.1) per 100,000 in 2000 to 9.2 cases (8.1–10.5) per 100,000 people in 2018 (β = 0.27, p < 0.001).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.2.2-11"></a>

###### Juvenile and pediatric Huntington's disease: proportion in Enroll-HD

> “50 compared with 7544 adult (0.66%) and 22 out of 16,124 family participants (0.14%) were pediatric.”

Source: [Achenbach and Saft (2021)](https://pubmed.ncbi.nlm.nih.gov/34049236/)

Additional sources: [Yohrling et al. (2020)](https://www.neurology.org/doi/10.1212/WNL.94.15_supplement.954)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases

> “Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents”
> “Europe, North America, Latin America, and Australasia”
> “and has recruited almost 25,000 participants”
> “Central to the clinical research platform is the Enroll-HD study (NCT01574053), a prospective longitudinal observational study that collects natural history data in HD gene-expansion carriers (HDGECs) and non-HDGEC controls.”
> “The Enroll-HD platform has been designed with the benefit of experience gained from several foundational HD studies”
> “REGISTRY, PREDICT-HD, COHORT, and TRACK-HD/Track On-HD (12–16).”
> “At their annual study visit, each participant is required to complete a core battery of assessments; extended and optional assessments are completed at the discretion of the PI and participant, respectively (Table 2).”
> “PDSs are prepared from the Enroll-HD study database every 1–2 years and include a large majority of the collected variables.”

Source: [Sathe et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8416308/)

<a id="topic-2.2.1.3-2"></a>

###### TRACK-HD: 12-month changes in premanifest and early Huntington's disease

> “TRACK-HD is a prospective observational study of Huntington's disease (HD) that examines disease progression in premanifest individuals carrying the mutant HTT gene and those with early stage disease.”
> “We report 12-month longitudinal changes, building on baseline findings.”
> “Whole-brain atrophy rates were 0·20% (95% CI 0·05-0·34; p=0·0071) per year higher in preHD participants and 0·60% (0·44-0·76; p<0·0001) in early HD patients, and caudate atrophy rates were 1·37% (0·99-1·75; p<0·0001) per year higher in preHD and 2·86% (2·34-3·39; p<0·0001) in early HD.”
> “Relative to controls, decline in cognition and quantitative motor function was detectable in both pre- and early HD, as was deterioration in oculomotor function in early HD.”

Source: [Tabrizi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21130037/)

<a id="topic-2.2.1.3-3"></a>

###### Rate of functional decline on Total Functional Capacity: cohort of 960 participants followed prospectively

> “The annual rate of functional decline was measured using the Total Functional Capacity Scale (TFC) and the Independence Scale (IS) in 960 patients with definite HD followed prospectively for a mean of 18.3 months.”
> “The TFC score declined at a rate of 0.72 units/year (standard error [SE] 0.04) and the IS score declined at a rate of 4.52 units/year (SE 0.23).”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-2.2.1.3-4"></a>

###### Enroll-HD progression model: trajectories of functional, motor, and cognitive decline

> “We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates.”
> “Our analysis revealed that TFC and TMS are best characterized by logistic-like trajectories while cognitive scores (SDMT and SWR) display an exponential-like decline (Figure 1, B and C).”
> “These results highlight the temporal differences in the rate of progression captured by different clinical end points and emphasize that individuals who exhibit rapid progression according to one clinical score may not necessarily exhibit fast progression according to another.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.1.3-5"></a>

###### GENERATION HD1 placebo arm compared with Enroll-HD natural history on Total Functional Capacity

> “We observed that for the functional score (TFC), the progression during the trial aligns with the natural history progression, showing no sign of a relevant placebo response (Figure 4A).”
> “It is important to note that our analysis revealed that a placebo response initially leads to an improvement after baseline, but after accounting for this initial improvement, the rate of progression between the GENERATION HD1 placebo arm and Enroll-HD cohorts remained consistent.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.1.3-6"></a>

###### Age at onset and prodromal phase

> “The mean age of onset is approximately 45 years”
> “About two thirds of individuals first present with neurologic manifestations; others present with psychiatric changes.”
> “These subtle changes can occur as early as 15-20 years prior to the clinical onset of manifest HD.”
> “In approximately 25% of individuals with HD, the onset is delayed until after age 50 years, with some after age 70 years”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.3-7"></a>

###### Prodromal change detected before diagnosis: PREDICT-HD

> “1078 individuals with a CAG expansion were included in this analysis. Participants were followed up for a mean of 5·1 years (SD 3·3, range 0·0-12·0). 225 (21%) of these participants received a motor diagnosis of Huntington's disease during the study.”

Source: [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)

> “This work showed that measurable brain and behavioral changes can be detected up to 15 years before an HD diagnosis.”

Source: [NINDS (2026)](https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease)

<a id="topic-2.2.1.3-8"></a>

###### Disease stages: Huntington's Disease Integrated Staging System

> “The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3).”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.1.3-9"></a>

###### Progression in premanifest and early disease: TRACK-HD

> “In the preHD-B group, several quantitative motor and cognitive tasks showed significantly increased rates of decline at 36 months, compared with controls, whereas few had at 24 months.”

Source: [Tabrizi et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23664844/)

> “For either score, initial progression age and then acceleration rate were highly CAG repeat length dependent. The acceleration continues through at least stage II disease.”

Source: [Langbehn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6692683/)

<a id="topic-2.2.1.3-10"></a>

###### Survival after onset and age at death

> “In late stages of HD, motor disability becomes severe, and the individual is often totally dependent, mute, and incontinent. The median survival time after onset is 15 to 18 years (range: 5 to >25 years). The average age at death is 54 to 58 years”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “For these fully ascertained subjects, the range, mean, SD, and median of duration values were 0–46, 15.4, 6.8, and 15 years, respectively.”
> “We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length.”

Source: [Keum et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4746370/)

<a id="topic-2.2.1.3-11"></a>

###### Mortality relative to the general population: UK cohort

> “The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2). Median age at death in individuals with HD and controls was 71 (IQR 59–79) and 81 (IQR 73–86) years, respectively. Individuals with HD were at 4.5 times greater risk of death than controls (hazard ratio 4.51, 95% CI 3.36–6.06, p < 0.001) after multivariable adjustment of baseline covariates (Figure S1).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.3-12"></a>

###### Age at death and causes of death: Norwegian national registries

> “Mean age at death for individuals with HD was found to be 63.9 years (NCDR) and 61.7 years (CRD), compared to a mean of 76.9 years in the general population (NCDR).”
> “In 73.5% of individuals with HD, the underlying cause of death was HD, followed by cardiovascular diseases, cancer and respiratory diseases. The most common immediate cause of death was respiratory diseases (44.2%). Suicide was a more common cause of death in the population with HD (2.3%) compared to the general population (1.3%).”

Source: [Solberg et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5870025/)

<a id="topic-2.2.1.3-13"></a>

###### Causes of death: aspiration pneumonia

> “Two hundred twenty four charts of deceased HD patients were reviewed, of which 216 (111/104 male/female, one unknown) had records available, 147 listed a cause of death (Table 1), which was pneumonia in 81 (55%) cases.”
> “The conclusion is that the majority (86.8%) of our HD patients where the cause of death could be identified died from aspiration pneumonia.”

Source: [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)

<a id="topic-2.2.1.3-14"></a>

###### Suicide and suicidal ideation

> “Incidence of suicidal ideation, suicide attempt, and suicide are higher among those with HD relative to the non-HD population.”

Source: [Kachian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30875675/)

> “At baseline, 169 (8.0%) mutation carriers endorsed suicidal ideation.”
> “The 4-year cumulative incidence of suicidal ideation was 9.9%.”

Source: [Hubers et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23876196/)

> “The critical periods for suicide risk are just prior to receiving a diagnosis and later, when affected individuals experience a loss of independence”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.3-15"></a>

###### Juvenile Huntington's disease: progression and survival

> “Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths.”

Source: [Oosterloo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307030/)

> “Disease progression was more rapid in juvenile Huntington's disease (n=14) than in adult-onset Huntington's disease (n=52; generalised estimating equation model, p=0·0003). Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort (hazard ratio 2·18 [95% CI 1·08-4·40]; p=0·002).”

Source: [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)

Additional sources: [Rodrigues and Ferreira (2017b)](https://pubmed.ncbi.nlm.nih.gov/29052699/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Mutant huntingtin: toxic gain of function

> “In mutation carriers, huntingtin is produced with abnormally long polyglutamine sequences that confer toxic gains of function and predispose the protein to fragmentation, resulting in neuronal dysfunction and death.”

Source: [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)

> “The expanded polyQ tract confers a toxic gain of function, resulting in the dysregulation of vital cellular processes, which ultimately leads to protein aggregation and cell death”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses.”

Source: [McColgan and Tabrizi (2018)](https://pubmed.ncbi.nlm.nih.gov/28817209/)

<a id="topic-2.2.1.4-2"></a>

###### Striatal degeneration: neuropathological grading

> “The earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% are lost in grade 1 and that 95% are lost in grade 4”

Source: [Vonsattel et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/2932539/)

<a id="topic-2.2.1.4-3"></a>

###### Genetic modifiers of onset: DNA repair genes identified by GWAS

> “Association at MLH1 and pathway analysis of the full GWA results support a role for DNA handling and repair mechanisms in altering the course of HD.”

Source: [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524551/)

> “The timing of onset shows no significant association with HTT cis-eQTLs but is influenced, sometimes in a sex-specific manner, by polymorphic variation at multiple DNA maintenance genes, suggesting that the special onset-determining property of the uninterrupted CAG repeat is a propensity for length instability that leads to its somatic expansion.”
> “Four genes at 3 loci were significant after Bonferroni correction: FAN1 (p = 1.9E-22), MSH3 (1.9E-8), PMS1 (6.1E-7), and ASNSD1 (5.3E-6) with later onset associated with increased FAN1, PMS1, and ASNSD1 expression and decreased MSH3 expression.”

Source: [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6700281/)

> “Repeatedly implicated MMR genes include MSH3, MLH1, PMS1, PMS2, and LIG1”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.4-4"></a>

###### Genetic modifiers of progression: MSH3 and PMS1

> “The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis”
> “encodes an aminoacid change (Pro67Ala) in MSH3”
> “Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation.”

Source: [Hensman Moss et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28642124/)

> “Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage.”
> “In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7.”

Source: [Lee et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9118113/)

<a id="topic-2.2.1.4-5"></a>

###### Somatic CAG repeat expansion in striatal projection neurons

> “We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost.”
> “We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene, and that HD pathogenesis is a DNA process for almost all of a neuron’s life.”

Source: [Handsaker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11822645/)

> “Somatic expansion within the striatum correlates strongly with earlier disease onset”
> “In this model, somatic instability acts as a catalyst for expansion, while a subsequent toxic gain-of-function mechanism drives cell death once the repeat length crosses a critical threshold.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.4-6"></a>

###### PMS1 as a modifier of somatic CAG repeat expansion

> “Homozygous but not heterozygous inactivation of PMS1 also reduces CAG repeat expansion, supporting PMS1 as a genetic modifier of HD and a potential target for therapeutic intervention.”

Source: [McLean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11015039/)

<a id="topic-2.2.1.4-7"></a>

###### Multiple pathogenic mechanisms

> “Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally. Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course.”

Source: [Tabrizi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32796930/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Establishing the diagnosis: clinical findings and molecular genetic testing

> “The diagnosis of HD is established in a proband with suggestive findings and a heterozygous CAG trinucleotide repeat expansion in HTT identified by molecular genetic testing (see Table 1).”
> “Family history is consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations). Absence of a known family history does not preclude the diagnosis.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state.”

Source: [Stoker et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34413240/)

<a id="topic-2.2.1.5-2"></a>

###### Laboratory testing standards

> “Assays used to diagnose Huntington disease must be optimized to ensure the accurate and unambiguous quantitation of CAG repeat length.”

Source: [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/)

<a id="topic-2.2.1.5-3"></a>

###### Clinical motor diagnosis: diagnostic confidence level

> “Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset.”

Source: [Reilmann et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25164527/)

> “with the gene mutation for Huntington's disease but without a motor diagnosis (a rating below 4 on the diagnostic confidence level from the 15-item motor assessment of the Unified Huntington's Disease Rating Scale)”

Source: [Paulsen et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25453459/)

<a id="topic-2.2.1.5-4"></a>

###### Staging: Huntington's Disease Integrated Staging System

> “The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments.”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

> “If there are signs of neurodegeneration, evidenced by atrophy of the caudate or putamen, individuals are assigned to stage 1. If disease signs are measurable by the TMS or Symbol Digit Modalities Test (SDMT), they are classified as stage 2. Finally, if there is an impact on daily functioning as assessed by the Total Functional Capacity (TFC) or the Independence Scale, individuals are assigned to stage 3.”
> “Clinical motor diagnosis, or a Diagnostic Confidence Level (DCL) of 4, corresponds to the latter part of HD-ISS stage 2.”

Source: [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)

<a id="topic-2.2.1.5-5"></a>

###### Predictive genetic testing in at-risk individuals

> “Testing of asymptomatic adults at risk for HD is possible but requires careful deliberation, as there is currently no cure for the disorder”
> “Testing of asymptomatic at-risk adult family members usually involves pretest interviews in which the motives for requesting the test, the individual's knowledge of HD, the possible impact of positive and negative test results, and neurologic status are assessed.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Pre-manifest diagnosis should only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they carry the mutation or not.”

Source: [Roos (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3022767/)

<a id="topic-2.2.1.5-6"></a>

###### Biomarkers: plasma neurofilament light protein

> “Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next.”
> “In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036).”

Source: [Byrne et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5507767/)

<a id="topic-2.2.1.5-7"></a>

###### Neuroimaging

> “Regional atrophy of the caudate and putamen is among the earliest pathologic changes in HD”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

Additional sources: [MacLeod et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22642570/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Motor symptoms: chorea

> “Chorea, an involuntary movement disorder consisting of nonrepetitive, nonperiodic jerking of limbs, face, or trunk, is the major sign of HD. Chorea is present in most individuals and typically increases in severity during the first ten years.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-2"></a>

###### Motor symptoms: dystonia, bradykinesia, rigidity, and oculomotor disturbance

> “With advancing disease duration, chorea may decrease and other movement abnormalities such as bradykinesia, rigidity, and dystonia occur. Impairment in voluntary motor function is an early sign.”
> “Difficulty in initiating ocular saccades, slow and hypometric saccades, and problems in gaze fixation occur in up to 75% of symptomatic individuals”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Early in the disease, they are primarily hyperkinetic with involuntary chorea. In later stages, however, hypokinesia with bradykinesia and dystonia may predominate.”

Source: [Ajitkumar et al. (2025)](https://www.ncbi.nlm.nih.gov/books/NBK559166/)

<a id="topic-2.2.1.6-3"></a>

###### Motor symptoms: gait disturbance and falls

> “Compared to controls, Huntington patients had a decreased gait velocity (1.15 m/s versus 1.45 m/s, P < 0.001) and a decreased stride length (1.29 m versus 1.52 m, P < 0.001).”

Source: [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)

<a id="topic-2.2.1.6-4"></a>

###### Cognitive symptoms: executive dysfunction and progressive decline

> “A global and progressive decline in cognitive capabilities occurs in all individuals with HD. Cognitive changes include forgetfulness, slowness of thought processes, impaired visuospatial abilities, and impaired ability to manipulate acquired knowledge”
> “These initial changes often involve loss of mental flexibility and impairment of executive functions such as mental planning and organization of sequential activities.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management.”

Source: [Snowden (2017)](https://pubmed.ncbi.nlm.nih.gov/28961886/)

<a id="topic-2.2.1.6-5"></a>

###### Psychiatric symptoms: depression, irritability, apathy, and anxiety

> “Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety.”

Source: [Paulsen et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737562/)

> “Depression is the most common psychiatric manifestation, affecting 40% of individuals with HD, followed by anxiety”
> “Apathy is a common and disabling symptom that is related to disease stage and worsens with progression”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Apathy was already present in 32% of preHD-A increasing to 62% of early-HD patients.”

Source: [Martinez-Horta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26898966/)

<a id="topic-2.2.1.6-6"></a>

###### Psychiatric symptoms: suicidality

> “Eleven (20%) pre-motor and 20 (20%) motor symptomatic mutation carriers were considered suicidal compared to none of the non-carriers.”

Source: [Hubers et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22119091/)

<a id="topic-2.2.1.6-7"></a>

###### Other symptoms: weight loss

> “Individuals with HD tend to experience substantial weight loss, reduced muscle mass, and lower body mass index compared to unaffected individuals.”
> “Individuals usually have very high calorie requirements to simply maintain their weight.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-8"></a>

###### Other symptoms: dysarthria and dysphagia

> “Speech impairment reflects a combination of dysarthria and word-finding difficulties, and in advanced disease some individuals may progress to complete anarthria. Swallowing difficulties arise from incoordination of oral and pharyngeal muscles, and can lead to choking episodes and aspiration pneumonia, a frequent cause of death in HD.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-9"></a>

###### Other symptoms: sleep and circadian disturbance

> “The most common sleep problems reported by HD patients include insomnia, difficulties in falling asleep, frequent nocturnal awakenings, and excessive daytime sleepiness.”

Source: [Herzog-Krzywoszanska and Krzywoszanski (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474183/)

<a id="topic-2.2.1.6-10"></a>

###### Juvenile Huntington's disease: presentation

> “In the first decade of life, individuals with juvenile HD present with common clinical manifestations of behavior disturbance and impairment of school performance, followed by dysarthria, seizures, rigidity, gait disturbances, bradykinesia, and dystonia”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Seizures occur in 30 percent to 50 percent of children with this condition.”

Source: [MedlinePlus (2020)](https://medlineplus.gov/genetics/condition/huntington-disease/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Loss of functional independence

> “Most individuals are forced to give up their employment and depend increasingly on others for help, although they are still able to maintain a considerable degree of personal independence.”
> “In late stages of HD, motor disability becomes severe, and the individual is often totally dependent, mute, and incontinent.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “They will eventually lose the ability to work, drive, and manage tasks at home, and may qualify for disability benefits.”
> “People with advanced HD need full-time care to help with their day-to-day activities, and they ultimately succumb to pneumonia, heart failure or other complications.”

Source: [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)

<a id="topic-2.2.1.7-2"></a>

###### Neuropsychiatric symptoms and functional capacity: systematic review

> “Significant associations with decreased functional capacity were found most commonly with depression (N=7, median r=0.48) and apathy (N=5, median r=0.47).”

Source: [Sellers et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31466515/)

<a id="topic-2.2.1.7-3"></a>

###### Falls and injury

> “Twenty-seven patients (60%) reported two or more falls in the previous year and were classified as fallers. During prospective follow-up 40% reported at least one fall. A high proportion of falls (72.5%) caused minor injuries.”

Source: [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)

> “Three months before death, anxiety (11% vs. 5%, 2.11, 0.7–5.6, p = 0.15), depression (28% vs. 6%, 4.28, 1.72–8.67, p < 0.001), falls (25% vs. 8%, 2.5, 1.18–4.73, p < 0.05), insomnia (25% vs. 4%, 8.82, 3.62–20.19, p < 0.001) and fractures/breaks/sprains (20% vs. 10%, 1.83, 0.85–3.35, p = 0.09) were more prevalent in HD cases.”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.7-4"></a>

###### Pneumonia, weight loss, dementia, and other comorbidities after diagnosis

> “Incidence rates of the following were statistically higher in individuals with HD than controls: psychotic disorders, psychosis, insomnia, dementia, depression, pneumonia, weight loss and falls.”
> “The most commonly mentioned causes of death (any mention) were HD (78.3%), bronchopneumonia (unspecified) (15.9%), pneumonitis due to food and vomiting (10.4%), unspecified dementia (6.6%) and sepsis (6.6%) (Table S8).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.7-5"></a>

###### Aspiration pneumonia

> “It is most likely that dysphagia is the causative factor for this aspiration pneumonia.”

Source: [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)

<a id="topic-2.2.1.7-6"></a>

###### Institutionalization: skilled nursing facility placement

> “Among 4,809 subjects enrolled, 3,070 had clinically definite HD. Of these, 228 (7.4%) resided in SNF. The SNF residents' average age was 52 years, average disease duration was 8.6 years, and they were predominantly women (63%).”
> “In the Cox model, bradykinesia (HR 1.965, 95% CI 1.083 to 3.564), impaired gait (HR 3.004, 95% CI 1.353 to 6.668), and impaired tandem walking (HR 2.546, 95% CI 1.460 to 4.439) were predictive of SNF placement.”

Source: [Wheelock et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12654967/)

<a id="topic-2.2.1.7-7"></a>

###### Juvenile Huntington's disease: long-term motor morbidity and seizures

> “Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed over time in the HE subgroup.”

Source: [Fusilli et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30243861/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Huntington's disease

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### HDBOI study: EQ-5D-5L, SF-6D, and H-QoL-I scores by disease stage

> “A total of 2,094 PwHD were enrolled with completed eCRFs (100%) and PPIE-P forms (n = 482, 23%).”
> “The mean EQ-5D-5L (n = 336) utility score was 0.59 (SD, 0.27), with the highest mean utility scores [SD] in ES (0.72 [0.22]) followed by MS (0.62 [0.18]) and AS (0.37 [0.30]), p < 0.001.”
> “The mean SF-6D score (n = 482) was 0.57 (SD, 0.10), with mean values decreasing with advanced disease (ES, 0.61; MS, 0.56; AS, 0.50, p < 0.001).”
> “H-QoL-I mean scores (n = 482) also worsened with more advanced disease, from 0.58 for ES to 0.49 for MS and 0.37 for AS, p < 0.001.”
> “Overall proxy respondents reported on average worse outcomes than PwHD (self-reported) across all outcomes and disease stages suggesting a possible unawareness of deficits by PwHD.”

Source: [Rodriguez Santana et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9757103/)

<a id="topic-2.2.1.8.1-2"></a>

###### Health state utility values: systematic literature review

> “Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies.”
> “The EQ-5D index range was 0.89 - 0.72 for mild/prodromal HD and 0.71 - 0.37 for severe/late-stage disease.”
> “This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data.”

Source: [Sawant et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020898/)

<a id="topic-2.2.1.8.1-3"></a>

###### Health state utility values: EHDN REGISTRY SF-6D analysis

> “11,328 questionnaires were completed by 5560 respondents with HD in 12 European countries.”
> “Women generally had lower HSUVs than men, and HSUVs were consistently lower than population norms for those with HD in the UK, and dropped with increasing disease severity.”
> “with TFC score, Behavioural score, and male gender significant predictors of SF-6D values (p < 0.001).”

Source: [Hawton et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856291/)

<a id="topic-2.2.1.8.1-4"></a>

###### Stage-specific utility values applied in a U.S. cost-effectiveness model

> “Health utilities for SoC were derived from the Hawton et al. study”
> “that used SF-6D preference-based measures to estimate stage-specific utilities for HD.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

| Health state | Utility, base case | Range |
| --- | --- | --- |
| Early | “0.73” | “0.7–0.9” |
| Middle | “0.63” | “0.5–0.7” |
| Late | “0.57” | “0.4–0.6” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-2.2.1.8.1-5"></a>

###### Norway cross-sectional study: EQ-5D-3L values by disease phase

> “Mean HRQoL values declined across disease phases for the 84 participants; early phase (n = 34): mean = 0.84 (SD = 0.13), middle phase (n = 19): mean = 0.74 (SD = 0.10) and advanced phase (n = 31): mean = 0.65 (SD = 0.5).”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.1-6"></a>

###### Spain: H-QoL-I and EQ-5D-3L

> “Fifty-five patients and an equal number of caregivers participated.”
> “The usual activities and anxiety/depression were the most severely altered dimensions according to the EQ-5D-3L results.”
> “Increase of disease severity resulted in lower patient QoL.”

Source: [Dorey et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5065694/)

<a id="topic-2.2.1.8.1-7"></a>

###### Chorea health states: time trade-off utility values in the general population

> “Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively.”
> “Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively.”

Source: [Claassen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8990962/)

<a id="topic-2.2.1.8.1-8"></a>

###### HDQLIFE: development of a disease-specific HRQoL measurement system

> “Existing item banks and new item pools were field tested in 536 individuals with prodromal, early-, or late-stage HD.”
> “HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well as five new scales in order to provide a comprehensive assessment of HRQOL in HD.”

Source: [Carlozzi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108175/)

<a id="topic-2.2.1.8.1-9"></a>

###### HDQLIFE physical function measures: reliability and validity

> “A total of 510 individuals with Huntington's disease completed 2 Quality of Life in Neurological Disorders (Lower Extremity Function and Upper Extremity Function) and 3 Huntington's Disease Health-Related Quality of Life (Chorea, Speech Difficulties, and Swallowing Difficulties) measures.”
> “Reliabilities for the new patient reported physical functioning measures were excellent (all Cronbach's α > .92).”

Source: [Carlozzi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28556412/)

<a id="topic-2.2.1.8.1-10"></a>

###### Chorea and HRQoL: U.S. online survey using HDQLIFE

> “A total of 115 participants (n = 35 caregivers; n = 80 individuals with HD) were included in this study.”
> “Among those experiencing chorea (n = 83, 74% of respondents), 66% indicated it was 'Very Important' to manage chorea; however, only 47% agreed that their current medication regimen helped manage their movements.”
> “significantly higher Anxiety (P = 0.0423) and stigma (P < 0.0001) scores were observed among respondents with high chorea than in those with low chorea.”

Source: [Thorley et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6132452/)

<a id="topic-2.2.1.8.1-11"></a>

###### Determinants of HRQoL: functional capacity and depressive mood

> “Multiple regression analyses showed that functional capacity and depressive mood were significantly associated with HrQOL, in that greater impairments in HrQOL were associated with higher levels of depressive mood and lower functional capacity.”
> “Motor symptoms and cognitive function were not found to be as closely linked with HrQOL.”

Source: [Ho et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19097181/)

<a id="topic-2.2.1.8.1-12"></a>

###### Psychiatric burden: suicidal ideation and sleep disturbance in the HDBOI study

> “PwHD reported current (13%, n = 272) or previous (28%, n = 575) suicidal ideation, which was more common with advanced HD (ES, 11%; MS, 14%; AS, 15%; p < 0.05).”
> “Of 482 questionnaire respondents, 91% (n = 437) reported difficulty sleeping, which was more common with AS HD (p < 0.05; [p = 0.000]).”

Source: [Rodríguez Santana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11962051/)

<a id="topic-2.2.1.8.1-13"></a>

###### Psychiatric burden: suicidal ideation measured with HDQLIFE Concern with Death and Dying items

> “We examined 496 participants with premanifest or manifest HD.”
> “Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and suicidal plans (2.1%) than the general population (p < 0.0001).”

Source: [Wesson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6108173/)

<a id="topic-2.2.1.8.1-14"></a>

###### U.S. survey: individuals with HD and care partners compared with Parkinson's disease and the general population

> “IHD had greater comorbid anxiety (IHD = 51.2%, IPD = 28.8%, GP = 2.0%), and HD-CP had greater comorbid anxiety (HD-CP = 52.5%, PD-CP = 28.6%, GP-CP = 19.6%) and depression (HD-CP = 65.0%, PD-CP = 29.9%, GP-CP = 19.6%), relative to other cohorts (p < 0.05).”
> “Respective of their GP cohorts, IHD exhibited lower HRQoL (EQ-5D: 0.66 ± 0.21 vs. 0.81 ± 0.17) and greater depression (PHQ-9: 11.59 ± 7.20 vs. 5.85 ± 6.71), whereas HD-CP exhibited greater depression only (PHQ-9: 6.84 ± 6.38 vs. 4.15 ± 5.58) (p < 0.001).”

Source: [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/)

<a id="topic-2.2.1.8.1-15"></a>

###### Canada: HRQoL of individuals with HD and care partner strain

> “A total of 62 adult individuals with HD (or their proxies) and 48 care partners met defined eligibility criteria.”
> “For individuals with HD, the greatest HRQoL burden (i.e., lowest score) was for the SF-36v1 Role -Physical scale (46.8 [42.9]).”
> “Among care partners, 55.3% experienced high strain, as indicated by the CSI.”

Source: [Shaw et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9277690/)

<a id="topic-2.2.1.8.1-16"></a>

###### Caregiver burden: prospective longitudinal study of patient and caregiver pairs

> “105 caregiver/patient pairs were included in the analysis.”
> “Of the two clusters of patients with advanced disease, cluster A was characterized by high levels of irritability and obsessive-compulsive behaviors, with high and increasing burden (N = 30; 29%), cluster B, the more apathetic group, with low and decreasing burden (N = 22; 21%).”

Source: [Youssov et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)

<a id="topic-2.2.1.8.1-17"></a>

###### Caregiver burden: determinants in a U.S. clinic sample

> “Total functional capacity and being sole caregiver were significantly associated with higher caregiver burden via MCSI.”

Source: [Yu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30594932/)

<a id="topic-2.2.1.8.1-18"></a>

###### Caregiver burden: South Korea prospective cohort

> “Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study.”
> “A higher caregiver burden was associated with a more severe Shoulson-Fahn stage (p = 0.038) of the patients.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846961/)

<a id="topic-2.2.1.8.1-19"></a>

###### Caregiver burden: systematic review

> “Twelve studies were included in the review involving 569 caregivers of patients with HD.”
> “Neuropsychiatric symptoms and the hereditary nature of the disease have been identified as important correlates of caregiver strain.”

Source: [Poprelka et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40938830/)

<a id="topic-2.2.1.8.1-20"></a>

###### Patient and caregiver experience: ICER stakeholder input

> “Caregiver impact increases as the disease progresses and individuals become more dependent on others, with 24/7 care eventually needed, particularly during the last five years of life.”
> “Motor symptoms are also a prominent feature of the disease and affect individuals’ ability to walk, talk, eat, and sleep.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)

<a id="topic-2.2.1.8.1-21"></a>

###### Multigenerational burden: qualitative study across six European countries

> “Cognitive and psychiatric symptoms were particularly burdensome, driving declines in quality of life (QoL) and emotional well-being.”
> “Caregivers reported extensive physical, financial, and psychological strain, with many assuming care responsibilities from a young age or eventually caring for multiple relatives.”

Source: [Smith et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522420/)

Additional sources: [Hergert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33723593/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### U.S. commercial and Medicaid claims (2002 to 2009): direct medical costs by stage

> “Among 1272 HD patients, the mean age was similar in commercial (752 patients) and Medicaid (520 patients) populations”
> “The mean total annualized cost per patient increased by stage (commercial: $4947 (SD = $6040)-$22,582 (SD = $39,028); Medicaid: $3257 (SD = $5670)-$37,495 (SD = $27,111).”
> “The vast majority (73.8%) of Medicaid Late stage patients received nursing home care and the majority (54.6%) of Medicaid Late stage costs were associated with nursing home care.”
> “Key limitations include the classification of patients into a single stage, as well as a lack of visibility into full long-term care/nursing home-related costs for commercial patients.”

Source: [Divino et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23789925/)

<a id="topic-2.2.1.8.2-2"></a>

###### U.S. Medicare fee-for-service claims (2013 to 2017): costs versus matched beneficiaries and by stage

> “We identified 3,688 matched pairs of beneficiaries with and without HD.”
> “Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001).”
> “In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).”

Source: [Exuzides et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34730477/)

<a id="topic-2.2.1.8.2-3"></a>

###### U.S. Medicaid Analytic eXtract (2010 to 2014): costs versus matched beneficiaries and by stage

> “A total of 1,785 beneficiaries without HD were matched to 595 beneficiaries with HD (139 early-, 78 middle-, and 378 late-stage).”
> “The mean (SD) annual total costs were higher for beneficiaries with HD than beneficiaries without HD ($73,087 [$75,140] vs. $26,834 [$47,659], p <.001) and driven by inpatient costs ($45,190 [$48,185] vs. $13,808 [$39,596], p <.001).”
> “Total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $22,797 [$31,683] for early-stage HD vs. $55,294 [$129,290] for middle-stage HD vs. $95,251 [$60,197] for late-stage HD; p <.001).”

Source: [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285853/)

<a id="topic-2.2.1.8.2-4"></a>

###### U.S. MarketScan commercial, Medicaid, and Medicare Supplemental claims (2009 to 2018): HRU and costs per patient per month by stage

> “A total of 2,669 individuals with HD were identified. Of these, 1,432 (53.7%), 689 (25.8%), and 548 (20.5%) had early-, middle-, and late-stage HD at baseline, respectively.”
> “Mean total all-cause healthcare cost PPPM for individuals with HD was $2,889, and it was significantly higher in middle-stage individuals, at $7,988, compared with early- and late-stage individuals, at $3,726 and $5,125, respectively; p <0.0001.”
> “Our evaluations didn't include the indirect costs of HD, which may be substantial as HD typically affects people at their peak earning potential.”

Source: [Exuzides et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/35608039/)

<a id="topic-2.2.1.8.2-5"></a>

###### U.S. MarketScan claims: costs versus propensity-matched controls without HD

> “A total of 2,473 individuals with HD and 9,522 matched non-HD controls were identified.”
> “Mean total costs (2018 USD PPPM) for the HD cohort ($2,260 [SD = $4,682]) were twice the total costs in the non-HD cohort ($1,056 [SD = $3,078]) (P < 0.0001) and were highest across all disease stages.”

Source: [To et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373050/)

<a id="topic-2.2.1.8.2-6"></a>

###### U.S. MarketScan claims: late-onset versus adult-onset HD

> “In total, 763 individuals with LoHD and 1,073 individuals with AoHD were matched with 3,762 non-HD controls.”
> “In the 12 months post-index, mean total costs for the LoHD cohort ($29,055) were significantly higher than for non-HD controls (≥60 years old: $17,286; 21-59 years old: $12,688; p <.001) and similar to total costs in the AoHD cohort ($31,701; p =.47).”

Source: [To et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37350423/)

<a id="topic-2.2.1.8.2-7"></a>

###### U.S. MarketScan claims (2017 to 2021): HD-related costs by diagnosing provider type

> “Three hundred and forty eligible patients had a mean age at diagnosis of 49 years.”
> “HD-related mean costs totaled $2,489 ($1,179 inpatient and $1,310 outpatient).”
> “Patients diagnosed by neurologists had significantly lower HD-related total non-medication costs vs. those diagnosed by PCPs (-$2,256; p < 0.05).”

Source: [Kim et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39373538/)

<a id="topic-2.2.1.8.2-8"></a>

###### Systematic review of cost-of-illness studies: annual costs by stage and cost type (2023 U.S. dollars)

| Cost type and study | “Early” | “Middle” | “Late” |
| --- | --- | --- | --- |
| Inpatient, Divino | “1150” | “5045” | “9216” |
| Inpatient, Exuzides | “1225” | “4250” | “22,228” |
| Inpatient, Patel | “791” | “3,070” | “65,465” |
| Outpatient, Divino | “2956” | “10,508” | “30,104” |
| Outpatient, Exuzides | “4736” | “10,361” | “13,665” |
| Outpatient, Patel | “5676” | “11639” | “6226” |
| Drug, Divino | “2483” | “4518” | “4838” |
| Drug, Exuzides | “15,663” | “16,790” | “23,944” |
| Drug, Patel | “6330” | “14149” | “13,108” |
| Caregiving, Jones | “6073” | “44,662” | “133,200” |
| Caregiving, Silva-Pardes | “6041” | “16,502” | “21,438” |

Source: [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)

<a id="topic-2.2.1.8.2-9"></a>

###### Systematic review of cost-of-illness studies: synthesis

> “Only five studies were included for extraction and synthesis including three from the USA, one from the United Kingdom (UK), and one from Peru.”
> “Outpatient costs were approximately 2.5 times greater than inpatient costs for early and middle stages of HD.”
> “Among all the costs associated with HD, annual caregiver cost emerges as the most significant costs in the economic burden of HD, ranging from a minimum of $6041 for early stage to a maximum of $133,200 for late-stage HD.”

Source: [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/)

<a id="topic-2.2.1.8.2-10"></a>

###### Global systematic review: annual costs by region (2024 U.S. dollars)

> “Out of the initial 608 de-duplicated articles, 19 full-text articles were included.”
> “Annual costs in 2024 USD ranged significantly by region: Americas ($2542-$90,515), Europe ($40,000-$215,020), Asia ($1915-$7132), and Oceania ($3678-$8721).”

Source: [Gokhale and Villa Zapata (2025)](https://pubmed.ncbi.nlm.nih.gov/39973389/)

<a id="topic-2.2.1.8.2-11"></a>

###### HDBOI study (France, Germany, Italy, Spain, United Kingdom, United States): direct, nondirect, and indirect costs

> “HDBOI cost estimates were €12,663 (n = 2094) for direct medical costs, €2984 (n = 359) for nondirect medical costs, and €47,576 (n = 436) for indirect costs.”
> “Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were €9220 (n = 846), €11,885 (n = 701), and €18,985 (n = 547) for ES, MS, and AS, respectively.”
> “Costs show large variations between patients and countries.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-12"></a>

###### HDBOI study: design, participants, and costing methods

> “The HDBOI study is a noninterventional, retrospective, cross-sectional, international burden of illness study of people with diagnosed HD in France, Germany, Italy, Spain, the UK, and the USA.”
> “A total of 2094 PwHD were enrolled in the HDBOI study, 40% of whom (n = 846) were classified as ES, 34% as MS (n = 701), and 26% as AS (n = 547; Table 1).”
> “Information regarding HD-related health care resource use used to compute direct medical costs was available for all 2094 PwHD. Information on direct nonmedical costs was available for 359 PwHD and indirect costs for 436 PwHD.”
> “Costs are reported in 2020 euros for all outcomes”
> “To minimize underestimation of costs due to potentially reduced care interactions during the coronavirus disease 2019 (COVID-19) pandemic, health care resource use (used to compute direct medical costs) was extracted for a set time period before the pandemic (March 2019 through March 2020).”
> “For actively employed PwHD and caregivers, productivity loss was quantified as the number of days missed from work due to HD in the past 3 months multiplied by the country average salary per day.”
> “For those unable to work due to HD, an opportunity cost was assigned based on 1 year of average salary per country.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-13"></a>

###### HDBOI study: mean annual costs by disease stage (2020 euros)

| Cost category | Total, mean (SD) | Early stage, mean (SD) | Mid stage, mean (SD) | Advanced stage, mean (SD) |
| --- | --- | --- | --- | --- |
| Direct medical costs | “€12,663 (€34,012)” | “€9220 (€31,855)” | “€11,885 (€31,827)” | “€18,985 (€38,811)” |
| Direct nonmedical costs | “€2984 (€3627)” | “€2275 (€3530)” | “€2956 (€3632)” | “€4180 (€3500)” |
| Indirect costs | “€47,576 (€47,985)” | “€35,859 (€44,874)” | “€51,996 (€45,549)” | “€56,947 (€51,723)” |
| Total costs | “€62,372 (€51,197)” | “€42,477 (€45,651)” | “€64,688 (€53,698)” | “€86,177 (€44,966)” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-14"></a>

###### HDBOI study: cost drivers and mean annual cost components by stage (2020 euros)

> “Inpatient hospitalizations and residential care were the primary drivers of direct medical costs”
> “Total costs (sum of direct medical, nonmedical, and indirect costs), available for a subsample of 307 PwHD (patients with a completed eCRF, PPIE-P, and PPIE-C), were driven primarily by indirect costs, which accounted for 84%, 80%, and 66% of ES, MS, and AS total costs, respectively (Appendix Table A2).”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
| --- | --- | --- | --- |
| Consultations | “€727 (€1216) n = 829” | “€767 (€975) n = 693” | “€1051 (€1335) n = 545” |
| Hospital inpatient | “€35,803 (€102,653) n = 28” | “€30,698 (€39,581) n = 23” | “€12,658 (€42,550) n = 60” |
| Treatment | “€6333 (€25,525) n = 667” | “€6539 (€28,257) n = 571” | “€7922 (€26,248) n = 454” |
| Residential care | “€41,879 (€46,946) n = 16” | “€56,673 (€40,806) n = 26” | “€45,977 (€31,915) n = 98” |
| Professional caregiver | “€1286 (€4355) n = 204” | “€2308 (€9831) n = 164” | “€2582 (€8632) n = 114” |
| State support, patient | “€841 (€2123) n = 204” | “€1199 (€2497) n = 164” | “€2677 (€3437) n = 114” |
| Lost productivity, PwHD | “€23,216 (€16,848) n = 75” | “€31,824 (€13,934) n = 109” | “€34,343 (€10,295) n = 98” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-15"></a>

###### HDBOI study: mean annual costs by country (2020 euros)

> “Direct nonmedical costs were highest in Italy (€3977) and the UK, and indirect costs were highest in the USA (€74,228 [$90,187]), the UK, and Italy”
> “The HDBOI study reported direct medical costs of €27,743 in the USA and a substantial indirect cost burden of €74,228 from lost work productivity.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Country | Direct medical costs | Indirect costs |
| --- | --- | --- |
| France | “4167” | “39471” |
| Germany | “11560” | “39451” |
| Italy | “6934” | “47048” |
| Spain | “5814” | “43547” |
| United Kingdom | “12606” | “52472” |
| United States | “27743” | “74228” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-16"></a>

###### HDBOI study: stated limitations of the cost estimates

> “Because recruitment was driven through clinician office visits, AS patients may have been underrepresented if they were admitted to long-term residential or nursing care homes.”
> “Cost estimates for AS PwHD may have been underestimated due to the small sample of patients with advanced disease and subsequent subgroup analyses.”
> “For Germany, direct medical costs may have been underestimated, as only copayments were publicly available, which do not reflect the true cost of the service delivered.”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.2-17"></a>

###### United Kingdom EHDN REGISTRY: annual societal costs by TFC stage (2013 pounds)

| Category | “Stage I: TFC 11–13 (n = 43)” | “Stage II: TFC 7–10 (n = 37)” | “Stage III: TFC 3–6 (n = 38)” | “Stage IV: TFC 1–2 (n = 13)” | “All stages (n = 131)” |
| --- | --- | --- | --- | --- | --- |
| Informal care, mean | “£1073.86” | “£4941.41” | “£21 051.79” | “£62 784.00” | “£14 085.24” |
| Total, mean | “£2250.06” | “£11 867.76” | “£29 671.91” | “£89 759.62” | “£21 605.08” |

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

<a id="topic-2.2.1.8.2-18"></a>

###### United Kingdom EHDN REGISTRY: cost drivers

> “The mean annual cost per person with HD was £21 605. The largest proportion of this cost (65%) was due to informal care (£14 085).”
> “This equates to £195 million per year in the UK.”

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

<a id="topic-2.2.1.8.2-19"></a>

###### Norway: six-month healthcare and societal costs

> “Total six-month healthcare costs and total societal costs were € 18,538 and € 66,789 respectively.”
> “Main six-month cost components for the three disease phases were informal care costs (€ 30,605) accounting for approximately half the total societal costs, and costs due to production loss (€ 18,907) being slightly higher than the total healthcare costs.”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.2-20"></a>

###### Long-term care in advanced HD: North American systematic literature review

> “Most patients with advanced HD receive LTC in a nursing home (35%) or at home (32%), with fewer patients receiving LTC from hospitals, hospices, and multi-setting facilities”
> “A long period of time is spent in both nursing home and hospice care, leading to sizeable annual costs for this care provision.”

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

<a id="topic-2.2.1.8.2-21"></a>

###### Hospice and palliative care utilization in the United States

> “Of the 164,032 patients admitted to these hospices, 101 (0.06%) had a primary diagnosis of HD.”
> “Patients had a median length of stay in hospice of 42 days, which was significantly longer than that of other hospice patients in the sample (17 days), P < 0.001.”

Source: [Johnson et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916295/)

> “8521 patients with HD were admitted to the hospital. Of those, 321 (3.8%) received specialty PC.”

Source: [Sokol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9436638/)

<a id="topic-2.2.1.8.2-22"></a>

###### Predictors of health care utilization: Enroll-HD Northern America

> “Visits from 1,631 participants in the Northern America region from the Enroll-HD study were included in this study.”
> “Clinical factors, such as psychiatric symptoms, functional ability, and comorbidities, were associated with use of multiple types of health care services.”

Source: [Ogilvie et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12021023/)

<a id="topic-2.2.1.8.2-23"></a>

###### Employment loss by disease stage: Enroll-HD

> “At baseline visit, 47.5% of patients with TFC score 11–13 (n=2,512) were unemployed; 19.9% of them due to illness and 15.4% were on sick leave.”
> “89.8% of patients with TFC score 7–10 (n=2,794) were unemployed; 37.8% of them due to illness and 19.7% were on sick leave.”
> “By 4 years post-clinical diagnosis, <20% patients stayed employed.”

Source: [Ko et al. (2020)](https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/)

<a id="topic-2.2.1.8.2-24"></a>

###### Employment and work productivity: HDBOI participants

> “Approximately 27% of the PPIE-P sample reported stopping work early (i.e., retiring) due to HD.”
> “Of those who reported being employed for pay overall work productivity loss increased with disease severity: 43% in ES, 55% in MS, and 57% in AS.”

Source: [Rodríguez-Santana et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-patient-poster-final-version-pdf.pdf)

<a id="topic-2.2.1.8.2-25"></a>

###### Employment: chorea and cognitive decline

> “Patients with chorea were less likely to be employed full-time (16.7% vs 25.7%; P<0.04) and more likely to be on long-term sick leave (17.4% vs 5.0%; P<0.01).”

Source: [Claassen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8216765/)

> “For every year delay in cognitive symptom onset, there was a 0.806 year increase in age at leaving work (SE = 0.030, p < 0.001, adj-R2 = 0.628).”

Source: [Watkins et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30198875/)

> “Twenty-three studies were identified and showed that while employment and working capacity in HD are negatively influenced by cognitive decline and motor impairments, apathy already plays a role in the prodromal stage.”

Source: [van der Zwaan et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35379551/)

<a id="topic-2.2.1.8.2-26"></a>

###### Canada (Alberta): direct healthcare costs under a universal public system

> “The mean total all-cause direct healthcare costs were $23,211 [$38,599] per person-year, with hospitalizations accounting for 57.8% of all-cause costs.”
> “Costs were higher among individuals with a long-term care stay, a proxy for disease severity.”

Source: [Shaw et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/35073826/)

<a id="topic-2.2.1.8.2-27"></a>

###### Other countries: Israel, China, Peru, Brazil, and Germany

> “Total healthcare and medication costs per patient (US dollars) were significantly higher for PwHD than controls ($7,343 vs. $3,625; P < 0.001).”

Source: [Barer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10366633/)

> “The average annual direct medical cost, direct non-medical cost, and indirect cost were 3,265.65, 805.82, and 801.97 Euros, respectively.”

Source: [Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38142687/)

> “The average annual cost of HD reached USD 8120 per patient in 2015.”
> “The mean cost of HD increased with the degree of patient dependency: from USD 6572 for Barthel 4 & 5 (slight dependency and total independency, respectively) to USD 23,251 for Barthel 1 (total dependency).”

Source: [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)

> “Significant economic impacts were observed, with average annual direct medical costs of $4686.82 per HD patient.”
> “Thirty-three out of 34 HD patients were unemployed or retired, and 16 relied on government benefits, reflecting broader socioeconomic implications.”

Source: [da Silva van der Laan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39150831/)

> “Physical therapy was the most often used medical aid in HD patients (46.4%). Nursing services and speech therapy were used by 27.9 and 22.7% of HD patients, respectively, whereas use of psychotherapy was rare (3.2%).”

Source: [Ohlmeier et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6905058/)

<a id="topic-2.2.1.8.2-28"></a>

###### U.S. indirect and out-of-pocket costs: HD-Charge survey

> “The indirect and out-of-pocket costs of HD in the US have not been quantified.”
> “Quantify out-of-pocket expenses for HDGECs and companions”

Source: [ClinicalTrials.gov NCT03628235](https://clinicaltrials.gov/study/NCT03628235)

Additional sources: [Ekkel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37269816/); [Winder et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30103341/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Huntington's disease on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Informal care and caregiver productivity costs: HDBOI study (2020 euros)

> “Indirect costs for informal care were calculated as the total number of hours per week of informal care multiplied by the number of weeks per year. Total number of hours per year was multiplied by the country average salary per hour.”
> “Caregiver state support accounted for 58%–75% of all direct nonmedical costs. Indirect costs were driven by lost productivity for PwHD (34%–42%) and costs of informal care requirements (40%–42%; Appendix Table A2).”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
| --- | --- | --- | --- |
| Informal care | “€27,760 (€37,790) n = 121” | “€30,243 (€37,046) n = 120” | “€37,758 (€45,515) n = 83” |
| Lost productivity, caregiver | “€18,225 (€19,864) n = 33” | “€12,988 (€15,621) n = 46” | “€17,280 (€19,266) n = 49” |
| State support, caregiver | “€5134 (€5834) n = 22” | “€5897 (€5098) n = 36” | “€4778 (€3359) n = 43” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.3-2"></a>

###### Informal caregiver time and objective burden: France

> “We included 80 ICs (mean [SD] age 57 [12.9] years, 60% women) in charge of 80 individuals with early to advanced stage HD”
> “The mean hours of informal care time was high: 7.3 (7.9) h/day (range 0-24); the mean professional home care was 2.8 (2.8) h/day (range 0.1-12.3).”
> “The burden was partially related to the multiplex caregiving status (19%). Protective factors lowering the IC burden included the absence of financial hardship (57%), a strong social network (16%) and keeping active on the job market outside home (46%).”

Source: [Bayen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36055643/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver employment and work productivity: HDBOI caregivers

> “A total of 37 (7%) respondents had to stop working because of their caregiving duties and 206 (41%) reported that their duties have impacted their career.”
> “Of the 206, approximately 59% were prevented from working more hours, 54% prevented from career progression, and 19% were required to choose an alternative career (See Table 3).”
> “High levels of informal care were reported, with an average of 34 hours of informal care per week.”
> “Overall impairment in caregiver daily activities increased with participant’s disease severity: 42% in ES, 48% in MS, and 52% in AS.”

Source: [Willock et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-caregiver-poster-final-version-pdf.pdf)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregivers of people with advanced HD in North America: systematic literature review

| Caregiver outcome | Quoted value |
| --- | --- |
| Mean time spent as primary carer (years) | “10.2 years” |
| Total hours of formal care per week | “43 hours” |
| Total hours of informal care per week | “41 hours” |
| Prevented career progression | “51%” |
| Prevented from working more hours | “70%” |
| Overall work productivity loss | “54%” |

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

> “Caregivers often give up their job, change careers, or reduce their hours to accommodate the long hours required to provide LTC.”

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

<a id="topic-2.2.1.8.3-5"></a>

###### Informal care as a share of societal cost: United Kingdom and Norway

> “Informal care was the largest driver of costs across all stages of HD; thus there is a need to also consider the needs of carers when planning services for people with HD.”

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

> “Our results highlight the crucial role the informal caregivers play in the care provided to HD patients in all disease phases. Future research should focus on the estimation of productivity loss among informal caregivers.”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.3-6"></a>

###### Out-of-pocket financing by families: Peru

> “Direct non-healthcare costs represented 78.3% of total cost, indirect costs 14.4% and direct healthcare costs the remaining 7.3%.”
> “Direct costs were primarily financed by patients and their families.”

Source: [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)

<a id="topic-2.2.1.8.3-7"></a>

###### Juvenile-onset HD: costs to the NHS and to families (England and Wales, 2020 pounds)

> “The overall mean JoHD cost to the NHS per year (2020) was £126,966 which varied according to disease severity, costing just under £11,000 in mild disease, £132,419 in moderate disease, and £221,797 in advanced JoHD.”
> “The proportion of indirect costs to families and carers was 64% for mild disease and 17% for advanced disease.”

Source: [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)

| Severity | “No. accessing” | Costs to family, “Mean (SD)” |
| --- | --- | --- |
| Mild | “9 (90%)” | “£19,269 (£17,995)” |
| Moderate | “7 (100%)” | “£33,118 (£45,657)” |
| Advanced | “14 (100%)” | “£48,696 (£55,825)” |
| All | “32 (97.0%)” | “£35,993 (£43,918)” |

Source: [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)

<a id="topic-2.2.1.8.3-8"></a>

###### Family financial and care needs: ICER stakeholder input

> “Many people with HD require care in a long-term care facility because of the heavy caregiving needs, and caregivers often need to change their career or work less to accommodate the needs of the individual with HD”
> “clinicians emphasized the importance of multidisciplinary care, including neurologists, psychiatrists, therapists, social workers, and geneticists, as families need assistance not only with medical issues but also with financial issues such as long-term care and life insurance, and testing for family members.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)

<a id="topic-2.2.1.8.3-9"></a>

###### At-risk family members: genetic discrimination in insurance

> “Discrimination was reported by 93 respondents (39.9%). Reported experiences occurred most often in insurance (29.2%), family (15.5%), and social (12.4%) settings.”
> “Family history of Huntington's disease, rather than the result of genetic testing, was the main reason given for experiences of genetic discrimination.”

Source: [Bombard et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694258/)

> “Across all three countries, a total of 46.2% of respondents report genetic discrimination or stigma based on either their family history of HD or genetic testing for the HD gene mutation.”
> “We report on the overall incidence of discrimination and stigma in the domains of insurance (25.9%), employment (6.5%), relationships (32.9%), and other transactions (4.6%) in the United States, Canada, and Australia combined.”

Source: [Erwin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3593716/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Cost of predictive genetic testing at HDSA Centers of Excellence in the United States

> “As of 2019 there were 47 HDSA COE’s in the US, and in the preceding year, they performed HD predictive genetic testing on a total of 777 individuals.”
> “The average cost of these tests was $1,157.12, with a range of $275-3,640 (Figure 1).”
> “The average cost for the various components of the predictive testing process included: $199.80 for genetic counselling, $278.40 for psychology, $666.33 for neuropsychology, $317.50 for neurology, $52.83 for social work, $352.80 for gene testing, and $210.80 for miscellaneous fees (Figure 2).”
> “59.6% of COE’s covered the cost of some component of the testing process out of COE grant funds, and 57.5% offered other financial assistance to offset the cost of the testing process.”

Source: [Massey et al. (2021)](https://www.mdsabstracts.org/abstract/cost-of-predictive-genetic-testing-for-huntingtons-disease-at-centers-of-excellence-in-the-us/)

<a id="topic-2.2.1.8.4-2"></a>

###### Predictive testing uptake among at-risk individuals

> “9407 predictive tests were performed across 23 UK centres.”
> “Using a prevalence figure of 12.3 × 10−5, the cumulative uptake of predictive testing in the 50% at-risk UK population from 1994 to 2014 was estimated at 17.4% (95% CI: 16.9–18.0%).”
> “Future therapies in HD will likely target presymptomatic individuals; therefore, identifying the at-risk population whose gene status is unknown is of significant public health value.”

Source: [Baig et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5027682/)

> “The uptake of predictive testing in the entire HD 50% at-risk population in 2001 was calculated by three methods giving a range of 12.3-14.6%. Uptake after 20 years was estimated to be 14.7%.”

Source: [Morrison et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20880124/)

<a id="topic-2.2.1.8.4-3"></a>

###### Fear of health insurance loss and out-of-pocket payment for testing: North America

> “After enrollment, 83 individuals [8.3%] pursued genetic testing. Their greatest concern was losing health insurance, and 41.6% of them [vs. 6.7% of those who did not pursue testing; P < 0.001] reported paying out of pocket for testing or other medical services to conceal their genetic risk from their insurer/employer.”
> “Among individuals who were tested, more United States residents [46.1%] than Canadian residents [0.0%; P = 0.02] paid out of pocket for health services or genetic testing.”

Source: [Oster et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2574833/)

<a id="topic-2.2.1.8.4-4"></a>

###### Insurance protections for genetic information in the United States

> “GINA prohibits group health plans, individual and group health insurance companies, and Medicare issuers from:”
> “GINA only provides for protection under health insurance and Medicare. Issuers of other types of insurance, such as long term care insurance, disability insurance, and life insurance may still request genetic information to determine eligibility and other coverage terms.”
> “Under GINA, an individual’s genetic test result is protected; however, health plans are permitted to use information about an individual’s disease when the disease has manifested.”

Source: [Huntington's Disease Society of America genetic testing and your rights](https://hdsa.org/find-help/healthcare-and-future-planning/genetic-testing-and-your-rights/)

<a id="topic-2.2.1.8.4-5"></a>

###### Access costs: travel, time away from work, and counseling

> “Distance is a structural barrier, and relates to the time and travel required to access PT, the financial and other opportunity costs associated with taking time away from work and family to attend appointments and the stress of navigating urban centers.”

Source: [Hawkins et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3548262/)

> “Genetic counseling is necessary for presymptomatic or symptomatic HD genetic testing, but the lack of access to counseling because of geography or expense is a critical gap for many patients.”
> “The main advantage of tele-GC was reduction in travel time for both in-person GC first (n = 16) and tele-GC first (n = 11) participants.”

Source: [Hall et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11515112/)

<a id="topic-2.2.1.8.4-6"></a>

###### Testing decisions when genetic services are fully funded: Israel

> “This pattern persists even when economic barriers are removed, demonstrating that psychological factors remain primary determinants of testing uptake.”

Source: [Inbar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13379509/)

<a id="topic-2.2.1.8.4-7"></a>

###### Demand for predictive testing after therapeutic trial news

> “the demand for predictive testing in at risk individuals significantly increased following the press release reporting the successful completion of the Ionis-HTTRx (RG 6042) trial.”

Source: [Bardakjian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31381522/)

<a id="topic-2.2.1.8.4-8"></a>

###### Reproductive genetic testing: cost-effectiveness of preimplantation genetic testing

> “Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for Huntington disease.”
> “In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268.”
> “Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer Huntington disease-affected offspring.”

Source: [Christensen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35618525/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 VMAT2 Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### EHDN international guideline: first-line treatment of chorea

> “Drug treatment should be considered if chorea causes the patient distress or discomfort.”
> “Tetrabenazine is one of the first-line treatments for this symptom (Grade A)”
> “unless the patient suffers from not well-managed depression or suicidal thoughts.”
> “Deutetrabenazine may indeed be proposed as an alternative to tetrabenazine for the treatment of chorea in countries where the marketing authorization is already obtained, like in the USA.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.1-2"></a>

###### AAN evidence-based guideline on chorea (retired 2022): recommendation

> “If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.”

Source: [Armstrong and Miyasaki (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413759/)

<a id="topic-2.2.2.1.1-3"></a>

###### AAN guideline status

> “This guideline is retired.”
> “Retired on July 16, 2022.”

Source: [American Academy of Neurology (2022)](https://www.aan.com/Guidelines/home/GuidelineDetail/558)

<a id="topic-2.2.2.1.1-4"></a>

###### German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine

> “The quality of data from RCTs is currently best for VMAT2 inhibitors”
> “The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.1-5"></a>

###### MDS evidence-based review of treatments for Huntington's disease

> “These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.”
> “Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

<a id="topic-2.2.2.1.1-6"></a>

###### Cochrane review of symptomatic treatments

> “22 trials (1254 participants) were included.”
> “Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.”

Source: [Mestre et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19588393/)

<a id="topic-2.2.2.1.1-7"></a>

###### HSG expert consensus: classes used for chorea in North American practice

> “Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.”
> “The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.”

Source: [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)

<a id="topic-2.2.2.1.1-8"></a>

###### Tetrabenazine: FDA-approved indication and boxed warning

> “XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease.”
> “XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-9"></a>

###### Tetrabenazine: label efficacy and functional outcomes in Study 1

> “As shown in Figure 1, Total Chorea Scores for patients in the drug group declined by an estimated 5.0 units during maintenance therapy (average of Week 9 and Week 12 scores versus baseline), compared to an estimated 1.5 units in the placebo group. The treatment effect of 3.5 units was statistically significant. At the Week 13 follow-up in Study 1 (1 week after discontinuation of the study medication), the Total Chorea Scores of patients receiving XENAZINE returned to baseline.”
> “In general, measures of functional capacity and cognition showed no difference between XENAZINE and placebo.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-10"></a>

###### Tetrabenazine: depression and sedation in the placebo-controlled trial

> “In a 12-week, double-blind, placebo-controlled study in patients with chorea associated with Huntington’s disease, 10 of 54 patients (19%) treated with XENAZINE were reported to have an adverse event of depression or worsening depression compared to none of the 30 placebo-treated patients.”
> “Sedation is the most common dose-limiting adverse reaction of XENAZINE.”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.1-11"></a>

###### Tetrabenazine: TETRA-HD randomized trial

> “The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks.”
> “There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.”

Source: [Huntington Study Group (2006)](https://pubmed.ncbi.nlm.nih.gov/16476934/)

<a id="topic-2.2.2.1.1-12"></a>

###### Deutetrabenazine: FDA boxed warning and label efficacy

> “AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease.”
> “Total Maximal Chorea Scores for patients receiving AUSTEDO improved by approximately 4.4 units from baseline to the maintenance period (average of Week 9 and Week 12), compared to approximately 1.9 units in the placebo group. The treatment effect of -2.5 units was statistically significant (p<0.0001).”

Source: [DailyMed AUSTEDO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0)

<a id="topic-2.2.2.1.1-13"></a>

###### Deutetrabenazine: First-HD randomized trial

> “Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002).”
> “Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.”

Source: [Huntington Study Group (2016)](https://pubmed.ncbi.nlm.nih.gov/27380342/)

<a id="topic-2.2.2.1.1-14"></a>

###### Valbenazine: FDA boxed warning and label efficacy

> “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease.”
> “The mean change in Total Maximal Chorea scores for patients receiving INGREZZA improved by 4.6 units (LS mean) from baseline to the end of the treatment period (average of Week 10 and Week 12), compared to 1.4 units in the placebo group. The treatment effect of -3.2 units was statistically significant (p<0.0001)”

Source: [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)

<a id="topic-2.2.2.1.1-15"></a>

###### Valbenazine: parkinsonism in Huntington's disease

> “Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington’s disease.”

Source: [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417)

<a id="topic-2.2.2.1.1-16"></a>

###### Valbenazine: KINECT-HD randomized trial

> “Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo).”
> “No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.”

Source: [Furr Stimming et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37210099/)

<a id="topic-2.2.2.1.1-17"></a>

###### HDSA physician's guide: indications for pharmacologic treatment of chorea

> “Symptoms that indicate the need for possible pharmacologic management of chorea include muscle pain, frequent dropping of items, repetitive injuries, falls associated with chorea of the trunk and limbs, poor sleep, and weight loss.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

Additional sources: [Reilmann (2013)](https://pubmed.ncbi.nlm.nih.gov/23674480/); [Frank et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39825184/); [Coppen and Roos (2017)](https://pubmed.ncbi.nlm.nih.gov/27988871/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Antipsychotics

<a id="topic-2.2.2.1.2-1"></a>

###### EHDN international guideline: second-generation neuroleptics for chorea and psychiatric symptoms

> “are first-line treatments for this symptom in particular when the patients have associated personality and/or behavioral or psychotic disorders. Monotherapy to treat chorea is preferred because combination therapy increases the risk of adverse effects and may complicate the management of non-motor symptoms.”
> “Second generation neuroleptics are the first line treatment for hallucinations and delusions (Grade C)”
> “In patients with aggressive behavior, the recommended first-line treatment is a neuroleptic (Grade C)”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.2-2"></a>

###### German Neurological Society guideline: tiapride as first-line antichoreic treatment

> “Because of the favorable profile of side effects, in particular with regard to extrapyramidal (akathisia, Parkinsonism) and behavioral (depression) symptoms, the consensus in the Delphi group was that tiapride should be considered as first line treatment.”
> “Comparative studies (comparing head-to-head compounds for their ability to suppress hyperkinesias short- and long-term) are unavailable.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.2-3"></a>

###### AAN guideline (retired 2022): insufficient data for neuroleptics

> “Data are insufficient to make recommendations regarding the use of neuroleptics or donepezil for HD chorea treatment (Level U).”

Source: [Armstrong and Miyasaki (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413759/)

<a id="topic-2.2.2.1.2-4"></a>

###### HDSA physician's guide: off-label neuroleptics for chorea

> “Individuals who do not tolerate tetrabenazine, or have other contraindications to its use, may benefit from off-label use of neuroleptics for reduction in chorea.”
> “Side effects of neuroleptics include apathy, sedation, akathisia, worsening of voluntary motor control, tardive dyskinesia and neuroleptic malignant syndrome.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### International expert survey: first-choice antichoreic drug by region

> “However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia.”

Source: [Burgunder et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3166256/)

<a id="topic-2.2.2.1.2-6"></a>

###### Olanzapine: one-year randomized open-label trial

> “Olanzapine improved chorea, behavior, and irritability, although with a slight increase in rigidity.”

Source: [Youssov et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41014964/)

Additional sources: [Reilmann (2013)](https://pubmed.ncbi.nlm.nih.gov/23674480/); [Coppen and Roos (2017)](https://pubmed.ncbi.nlm.nih.gov/27988871/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Antidepressants and Other Psychiatric Pharmacotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### EHDN international guideline: depression, irritability, and anxiety

> “An antidepressant may be suggested if depression occurs in HD (Grade B)”
> “It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI), or alternatively Mianserin or Mirtazapine, in case of sleep disruption.”
> “Whilst SSRIs are first lines for irritability (Grade C)”
> “SSRI or SNRI are first line treatments of anxiety, especially when associated with depression.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.3-2"></a>

###### EHDN international guideline: suicide risk assessment

> “Suicide risk should be assessed in HD irrespective of the stage, being particularly vigilant at the time of diagnosis and when the disease starts to impact on day-to-day life.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.3-3"></a>

###### HDSA physician's guide: pharmacotherapy for depression

> “There is no single preferred antidepressant for treating depression in HD.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### German Neurological Society guideline: psychiatric symptoms

> “There is hardly any data from RCTs or controlled studies on treating mental health problems in HD. Recommendations are therefore based on expert opinion.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.3-5"></a>

###### Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders

> “An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom.”
> “High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.”

Source: [Anderson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6294590/)

<a id="topic-2.2.2.1.3-6"></a>

###### Systematic review of pharmacological treatment of neuropsychiatric symptoms

> “Fifteen articles qualified for critical evaluation: 10 randomized controlled trials (RCTs) (five placebo-controlled and five cross-over) and five open label studies.”
> “As a result, convincing evidence that could guide clinical practice is lacking.”

Source: [Andriessen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998698/)

<a id="topic-2.2.2.1.3-7"></a>

###### MDS evidence-based review: psychiatric symptoms

> “There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Rehabilitation and Nutritional Therapies

<a id="topic-2.2.2.1.4-1"></a>

###### EHDN international guideline: physiotherapy and exercise

> “Early referral to a physiotherapist is recommended in order to facilitate the development of a therapeutic relationship, promote sustainable exercise behaviors and ensure long-term functional independence.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-2"></a>

###### EHDN international guideline: speech and language therapy and nutrition

> “Early referral to Speech and Language Therapists is recommended (Grade C)”
> “Good nutritional care is a fundamental element of the management of HD (Grade C)”
> “Early assessment by a dietitian or nutritionist, and regular timely reviews of nutritional needs are recommended.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-3"></a>

###### EHDN international guideline: cognitive symptoms

> “Based on present knowledge, no pharmacological treatment is recommended for the treatment of cognitive symptoms.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-4"></a>

###### Physical therapy clinical recommendations

> “We recommend the following specific physical therapy interventions for people with HD: aerobic exercise (grade A evidence), alone or in combination with resistance training to improve fitness and motor function, and supervised gait training (grade A evidence) to improve spatiotemporal features of gait.”

Source: [Quinn et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7080285/)

<a id="topic-2.2.2.1.4-5"></a>

###### German Neurological Society guideline: speech and occupational therapy

> “Therefore, involving speech therapists in the multidisciplinary care of HD patients is essential.”
> “Symptom-based psychosocial interventions such as psychological procedures, occupational therapy, and physical activity are recommended to stabilize and maintain everyday functions.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.4-6"></a>

###### MDS evidence-based review: nonpharmacologic interventions

> “Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Limitations of Current Therapies

<a id="topic-2.2.2.1.5-1"></a>

###### Summary

In a review of disease-modifying interventions, none of the pharmacological interventions proved effective as a disease-modifying therapy for HD, and the Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease.

- Chorea: in a review of 22 trials (1254 participants), only tetrabenazine showed clear efficacy for the control of chorea. An evidence-based review concluded that the data support only the use of VMAT2 inhibitors for specific motor symptoms. The prescribing information for tetrabenazine, deutetrabenazine, and valbenazine states that each can increase the risk of depression and suicidal thoughts and behavior in patients with HD, and tetrabenazine is contraindicated in patients who are actively suicidal or have untreated or inadequately treated depression. In the 12-week placebo-controlled tetrabenazine study, 10 of 54 patients (19%) reported depression or worsening depression compared with none of 30 placebo-treated patients; Total Chorea Scores returned to baseline at the Week 13 follow-up, 1 week after discontinuation, and measures of functional capacity and cognition showed no difference from placebo. The valbenazine prescribing information states that drug-induced parkinsonism can cause more functional disability than untreated chorea for some patients. Side effects of neuroleptics include apathy, sedation, akathisia, worsening of voluntary motor control, tardive dyskinesia, and neuroleptic malignant syndrome. One publication states that pharmacologic treatment of chorea remains underutilized in clinical practice.
- Psychiatric symptoms: the evidence-based review found no eligible evidence to support specific treatments for depression, psychosis, irritability, apathy, or suicidality. A review of fifteen articles concluded that convincing evidence to guide practice is lacking, and one guideline states that its recommendations on mental health problems are based on expert opinion.
- Cognitive symptoms: one guideline recommends no pharmacological treatment for cognitive symptoms.
- Nonpharmacological care: the evidence-based review found no eligible evidence to support physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.
- Evidence base: among 376 therapeutic studies conducted between 1965 and 2015, the authors of that guideline found one grade A study.

Source: [Mestre et al. (2009b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390161/); [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf); [Mestre et al. (2009a)](https://pubmed.ncbi.nlm.nih.gov/19588393/); [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/); [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda); [DailyMed AUSTEDO prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0); [DailyMed INGREZZA prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417); [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/); [Andriessen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998698/); [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/); [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.5-2"></a>

###### Summary: investigational therapies and regulatory history of ifezuntirgene inilparvovec

- Tominersen: in GENERATION HD1, treatment was stopped in March 2021 on the basis of an independent data monitoring committee's benefit-risk assessment, and the cUHDRS change at week 69 in the every-8-week group was significantly worse than placebo (−0.54 points, adjusted P=0.001). In GENERATION HD2, reductions in mHTT protein and NfL in 301 participants did not translate into a meaningful improvement in clinical outcomes, and Roche discontinued clinical development of tominersen.
- Pridopidine: the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) of the phase III PROOF-HD study were not met in the overall population. In its questions and answers on the withdrawal of the marketing authorisation application for pridopidine (Nurzigma), the European Medicines Agency noted that the validity and relevance of the subgroup results in patients not treated with antidopaminergic medicines had not been demonstrated.
- Ifezuntirgene inilparvovec (AMT-130): the sponsor stated at its BLA submission that there are currently no approved therapies to delay the onset or slow the progression of HD. The sponsor reported that, at an RMAT Type B meeting, the FDA agreed that Phase I/II data compared with a natural history external control may serve as the primary basis for a BLA submission under the Accelerated Approval pathway. After a pre-BLA meeting held on October 29, 2025, the FDA conveyed that the Phase I/II data were currently unlikely to provide the primary evidence to support a BLA submission. Final minutes of a Type A meeting held on January 30, 2026 stated that the FDA could not agree that the Phase I/II data compared with an external control were sufficient, and the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. After a subsequent Type B meeting, the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The third quarter 2026 Form 10-Q states both that the submission was announced in September 2026 and that the BLA was submitted in August 2026 and accepted for review in October 2026; it reports the acceptance as announced on November 2, 2026. The application was granted Priority Review with a PDUFA target action date of May 1, 2027, and the 48-month topline results were not part of the BLA.

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/); [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/); [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf); [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application); [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated); [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.2.2.1.5-3"></a>

###### Cochrane review of disease-modifying interventions

> “Only pharmacological interventions were included and none proved to be effective as a disease-modifying therapy for HD.”

Source: [Mestre et al. (2009b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390161/)

<a id="topic-2.2.2.1.5-4"></a>

###### Absence of disease-modifying therapy

> “There is currently no cure or treatment which can halt, slow or reverse the progression of the disease.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

> “Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.”

Source: [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application)

<a id="topic-2.2.2.1.5-5"></a>

###### Tetrabenazine: contraindication in depression

> “XENAZINE is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression”

Source: [DailyMed XENAZINE prescribing information (2019)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda)

<a id="topic-2.2.2.1.5-6"></a>

###### Limited trial evidence in a rare disease

> “In this work, based on therapeutic trials conducted between 1965 and 2015, only one grade A study was found among 376 studies analyzed, which is insufficient to eliminate or recommend enough products to meet the patients' needs.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.5-7"></a>

###### Investigational HTT lowering: tominersen phase 3 treatment stopped, with worse cUHDRS change at the every-8-week regimen

> “On the basis of an overall benefit–risk assessment by an independent data monitoring committee, treatment was stopped in March 2021”
> “In the every-8-week tominersen group, the mean change from baseline in the score on the cUHDRS at week 69 was significantly worse than that in the placebo group (−0.54 points, adjusted P=0.001)”
> “The role of antisense oligonucleotide–related toxic effects (possibly inflammatory in nature), as compared with total HTT lowering, on the outcomes observed in GENERATION HD1 cannot be distinguished, given the close relationship between drug exposure and HTT lowering.”

Source: [McColgan et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38055260/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: studied population and anticipated use

- Studied population: the U.S. Phase I/II study and the European Phase Ib/II study use the same early manifest criteria, enrolling males and females aged 25 to 65 years with a definitive clinical diagnosis of early manifest HD and a CAG repeat of ≥40. Key eligibility criteria in one presentation included a total functional capacity of 9-13, a diagnostic confidence level of 3 or 4, HD medications stable for the prior 3 months, and striatal volumes exceeding specified minima (putamen ≥ 2.5 cm3/side; caudate ≥ 2.0 cm3/side).
- Anticipated use: the sponsor states that no available therapy can delay onset or slow progression, and that available symptomatic treatments are only transiently effective and often associated with significant side effects. The sponsor's target profile is a one-time administration of a disease-modifying therapy into the striatum. ICER's assessment names usual symptomatic care (treatment for movement disorders, psychiatric and mood symptoms, physical therapy) as the comparator. A public comment asked ICER to incorporate HD staging (ISS-2 and ISS-3) into the scope, and authors of the HD Integrated Staging System state that it could facilitate trials in populations before clinical motor diagnosis.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.2.2-2"></a>

###### Summary: care setting

- Administration: in the Phase I/II studies, each treated patient received a single administration through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).
- Access to specialty care: clinical experts told ICER that about 30% of patients with HD receive specialty care with a movement disorders neurologist, and half of those receive care at an HD Center of Excellence, which raises concern about access to new treatments offered only at specialty centers. A public comment to ICER stated that access is limited to a few neurosurgical centers, that effects beyond four years are unknown, and that there are no retreatment data.
- Centers of Excellence: there are 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia, each providing a multidisciplinary team approach. HDSA's comment to ICER states that these centers can inform the treatment burden, access barriers, caregiver requirements, travel, follow-up, and infrastructure needed to deliver a new therapy.
- Payer analog: Aetna's criteria for eladocagene exuparvovec-tneq (Kebilidi) require precertification, prescription by or in consultation with a neurologist, geneticist, or physician specializing in inherited metabolic diseases, and administration in a medical center that specializes in stereotactic neurosurgery; the policy states that gene and cellular therapies must be administered at an Aetna GCIT Network unless the member's plan has elected otherwise.

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/); [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.2-3"></a>

###### Sponsor statement: absence of disease-modifying therapy and limits of symptomatic treatment

> “There is currently no available therapy that can delay onset or slow progression of the disease. Although some symptomatic treatments are available, they are only transiently effective and are often associated with significant side effects.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.2.2-4"></a>

###### Sponsor target profile: one-time administration into the striatum

> “Our goal for AMT-130 is to develop a gene therapy with the following profile:”
> “one-time administration of a disease-modifying therapy into the striatum, the area of the brain where Huntington’s disease is known to manifest;”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.2.2-5"></a>

###### Comparator care in the ICER assessment: usual symptomatic care

> “Usual symptomatic care (treatment for movement disorders [e.g., chorea], psychiatric and mood symptoms, physical therapy, etc.)”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.2-6"></a>

###### Access to specialty neurology care: clinical expert input to ICER

> “Clinical experts relayed that only about 30% of patients with HD get specialty care with a movement disorders neurologist, and only half of those patients get care at an HD Center of Excellence.”
> “This difficulty in accessing specialized neurology care results both in a long journey to diagnosis and concerns about patients’ ability to access new treatments that may only be offered at specialty centers.”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.2-7"></a>

###### HDSA Centers of Excellence and delivery of a new therapy: HDSA comment to ICER

> “HDSA also recommends that ICER engage directly with HDSA Centers of Excellence (COEs) as an important source of patient-centered expertise.”
> “COEs can also provide insight into the practical implications of a new therapy, including treatment burden, access barriers, caregiver requirements, travel, follow-up, and the infrastructure necessary to deliver specialized care.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.2-8"></a>

###### Neurosurgical center access, retreatment, and disease stage: public comment to ICER on the draft scope

> “These challenges are even greater here because effects beyond four years are unknown, access is limited to a few neurosurgical centers (creating geographic inequities), and there is no retreatment data.”
> “ICER should explicitly incorporate HD staging (e.g., ISS-2 and ISS-3) into the AMT-130 scope and align outcome measures to stage-specific treatment goals.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.2-9"></a>

###### Care setting analog: Aetna criteria for the gene therapy Kebilidi, administered at a stereotactic neurosurgery center

> “Note: Unless member's health plan has elected not to require, gene and cellular therapies must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network.”
> “Precertification of eladocagene exuparvovec-tneq (Kebilidi) is required of all Aetna participating providers and members in applicable plan designs.”
> “This medication must be prescribed by or in consultation with a neurologist, geneticist, or physician specializing in the treatment of inherited metabolic diseases.”
> “Kebilidi will be administered in a medical center which specializes in stereotactic neurosurgery; and”

Source: [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.2-10"></a>

###### Target stages: HD Integrated Staging System

> “These initial stages, which have only recently become a focus of study, are particularly promising as they may reveal the most effective targets for disease-modifying therapies.”

Source: [Sampaio et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11307057/)

<a id="topic-2.2.2.2-11"></a>

###### HD-ISS as a framework for earlier intervention

> “The adoption of the HD-ISS could facilitate the design of clinical trials targeting populations before clinical motor diagnosis and enable data standardisation across ongoing and future studies.”

Source: [Tabrizi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35716693/)

<a id="topic-2.2.2.2-12"></a>

###### Care setting: MRI-guided neurosurgical administration of AMT-130

> “Treated patients received a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.2.2.2-13"></a>

###### Specialist care setting: HDSA Centers of Excellence

> “HDSA Centers of Excellence provide a multidisciplinary team approach to Huntington’s disease care.”
> “There are currently 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia.”

Source: [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)

Additional sources: [Willock et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38108355/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary

- Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
- Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
- Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
- Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
- Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure press release, third quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [ICER research protocol (2026)](https://osf.io/download/eyjx6/); [ICER model analysis plan (2026)](https://osf.io/download/puega/); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/); [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/); [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Dose response: high dose compared with low dose at 48 months

> “At 48-months, high-dose patients compared to low-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC, consistent with a dose-dependent treatment effect.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.2.2.3-3"></a>

###### Baseline striatal volume as a predictor of progression in natural history data

> “Baseline Striatal Volume is a Predictor of Clinical Progression in TRACK-HD”
> “Baseline Volumetric Criteria Predicts cUHDRS Decline in the Absence of Other Covariates”
> “Baseline Volumetric Criteria Are No Longer Predictive of TFC Decline When Propensity Score Adjustments are Applied”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.2.2.3-4"></a>

###### Planned evaluation of treatment effect modification by subpopulation

> “Data permitting, we will evaluate the evidence for treatment effect modification by subpopulations defined by:”
> “Other relevant HD characteristics (e.g., HD staging [e.g., Huntington’s Disease Integrated Staging System (HD-ISS) stages 2 and 3], concomitant antidopaminergic medication, striatal volume, etc.)”

Source: [ICER research protocol (2026)](https://osf.io/download/eyjx6/)

<a id="topic-2.2.2.3-5"></a>

###### Heterogeneity and subgroup analyses not planned

> “No heterogeneity and subgroup analyses are planned as currently available trial data are insufficient to support them.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.3-6"></a>

###### Antidopaminergic medication as an effect modifier: public comment by Prilenia

> “Prilenia respectfully requests ICER consider the following:”
> “Concomitant antidopaminergic medications (ADMs) are a pharmacologically important covariate.”
> “In small sample size studies a chance imbalance in ADM use between groups can disproportionately shift group-level averages on functional scales, and limited statistical power constrains the ability to adjust for or stratify by ADM exposure, making it harder to distinguish a true treatment effect from an artifact of unbalanced background medication use.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Progression by subpopulation and endpoint: disease progression model

> “For instance, PIN and CAP can effectively enrich the population with patients more likely to progress, particularly when using TFC (Figure 5, A and B).”
> “Moreover, when using TFC as an end point, the progression rate in individuals with HD-ISS = 2 is not expected to be different from the rate in those with HD-ISS = 3, in contrast to other clinical measurements such as SMDT (Figure 5C).”
> “However, the weak correlation in progression rates between different clinical scores indicates that patients likely to progress based on one score may not necessarily progress based on other scores.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.2.3-8"></a>

###### Baseline covariates of functional decline: cohort of 960 participants

> “In multivariate analysis (n = 960), longer disease duration and better cognitive status at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology was the only factor associated with more rapid decline on the IS score.”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-2.2.2.3-9"></a>

###### Tominersen: exploratory subgroup finding tested in GENERATION HD2

> “GENERATION HD2 was initiated following exploratory analyses of the phase III GENERATION HD1 study, which suggested that younger participants with lower disease burden might derive benefit from lower-dose, less frequent administration of tominersen.”
> “After completion of the planned 16-month treatment period in all 301 participants, top-line analyses showed that tominersen was well tolerated and achieved significant reductions in mHTT protein and NfL concentrations compared with placebo.”
> “However, these biomarker effects did not translate into a meaningful improvement in clinical outcomes, and Roche therefore discontinued further clinical development of tominersen.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.2.2.3-10"></a>

###### Pridopidine: post hoc subgroup without antidopaminergic medication

> “PRECISE-HD seeks to build on findings from numerous large trials of pridopidine in HD that failed to demonstrate efficacy, most recently the phase III PROOF-HD study (NCT04556656),”
> “Although the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) were not met in the overall study population, post-hoc and sensitivity analyses suggested potential benefit among participants who were not receiving antidopaminergic medications.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.2.2.3-11"></a>

###### Pridopidine (Nurzigma): regulator assessment of the subgroup analyses

> “The active substance in Nurzigma, pridopidine, activates a protein called sigma-1 receptor (S1R).”
> “The Agency noted that the validity and relevance of the results of the analyses in the subgroup of patients (adults with early Huntington’s disease who were not treated with antidopaminergic medicines) from the main study have not been demonstrated.”

Source: [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary

- Procedure and monitoring analogs: the prescribing information for Kebilidi, a product administered by stereotactic neurosurgery, directs monitoring for procedure-related adverse events, including continuous cardiorespiratory monitoring during hospitalization, and the FDA review states that procedural complications can be mitigated by post-procedural monitoring. Aetna considers brain MRI for stereotactic planning and intraoperative navigation medically necessary for members being considered for Kebilidi.
- Long-term follow-up: FDA guidance recommends long-term follow-up of up to five years for AAV vectors, with a risk-based approach to duration for vectors capable of long term expression without integration, such as AAV.
- Multidisciplinary care: a multidisciplinary position paper recommends a multidisciplinary team, an individualised care and treatment plan for every patient and family, and a case manager or coordinator. The Huntington's Disease Society of America states that no one doctor or caregiver should manage all aspects of an HD case, and that the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life. HDSA Centers of Excellence provide neurologists, psychiatrists, social workers, therapists, counselors, and other professionals.
- Advance care planning: one guideline describes advance care planning as essential, including discussion of alternative feeding methods, and another recommends documenting living wills and care directives early and social worker support for financial assistance. In one study, engaging in advance care planning did not cause untoward effects on health-related quality of life or suicidal thoughts and behavior (STB), whose lifetime prevalence in HD approaches 30%.
- Palliative care: a review included 38 of 333 articles and found a low level of evidence for most topics. One publication states that referral to palliative care should be strongly considered for patients with pain, anxiety, sleep disturbances, and difficulty coping with the diagnosis.

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download); [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download); [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html); [FDA long term follow-up after gene therapy guidance (2020)](https://www.fda.gov/media/113768/download); [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/); [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf); [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/); [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full); [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/); [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/); [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/); [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)

<a id="topic-2.2.2.4-2"></a>

###### Post-procedural monitoring after Kebilidi administration: label and FDA review

> “Monitor patients for procedure related adverse events with KEBILIDI administration, including”
> “continuous cardiorespiratory monitoring during hospitalization.”

Source: [Kebilidi prescribing information (2024)](https://www.fda.gov/media/183530/download)

> “The major risks of KEBILIDI include procedural-related complications and dyskinesia and can be mitigated by post-procedural monitoring and use of dopamine antagonists, respectively.”

Source: [FDA Kebilidi summary basis for regulatory action (2024)](https://www.fda.gov/media/184353/download)

<a id="topic-2.2.2.4-3"></a>

###### Pre-procedure imaging in Aetna criteria for Kebilidi: stereotactic planning MRI

> “Brain MRI will be used for stereotactic planning and intraoperative navigation; and”
> “Aetna considers the following tests and procedures medically necessary for members being considered for treatment with Kebilidi:”
> “Brain magnetic resonance imaging (MRI) for stereotactic planning and intraoperative navigation.”

Source: [Aetna clinical policy bulletin 1073 (2026)](https://www.aetna.com/cpb/medical/data/1000_1099/1073.html)

<a id="topic-2.2.2.4-4"></a>

###### Long-term follow-up after AAV gene therapy: FDA guidance

> “In general, our current recommendations for the duration of a LTFU protocol based on product type are as follows:”
> “Up to five years for AAV vectors.”
> “Additionally, a risk-based approach for determining the duration of a LTFU protocol may be considered for vectors capable of latency (e.g., Herpesvirus), long term expression without integration (e.g., AAV), or vectors carrying gene editing components.”

Source: [FDA long term follow-up after gene therapy guidance (2020)](https://www.fda.gov/media/113768/download)

<a id="topic-2.2.2.4-5"></a>

###### EHDN multidisciplinary position paper: managed care network and case manager

> “The multidisciplinary team should be composed of different professionals who work closely together and interact within the group. It is also important to establish an individualised care and treatment plan for every single case of a patient and family. A case manager or coordinator may facilitate the work of the multidisciplinary team.”
> “This position paper reveals that there are key essential professional groups involved in the MDT who do not have an HD guideline available, like psychologists, social workers, nurses, case managers and general practitioners.”

Source: [Mühlbäck et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9887752/)

<a id="topic-2.2.2.4-6"></a>

###### HDSA physician's guide: team care and Centers of Excellence

> “No one doctor or one caregiver should attempt to manage all aspects of an HD case without assistance.”
> “Because there are no treatments which can slow, halt, or reverse the course of the disease, the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

<a id="topic-2.2.2.4-7"></a>

###### HDSA Centers of Excellence: team composition

> “Patients benefit from expert neurologists, psychiatrists, social workers, therapists, counselors and other professionals who have extensive experience working with families affected by HD and who work collaboratively to help families plan the best HD care program throughout the course of the disease.”

Source: [Huntington's Disease Society of America Centers of Excellence](https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence/)

<a id="topic-2.2.2.4-8"></a>

###### Advance care planning: EHDN guideline

> “Advanced care planning is essential and alternative feeding methods (PEG, see swallowing disorders) should be anticipated and discussed with relatives and patients still able to understand the benefits and risks of the intervention.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.4-9"></a>

###### Advance care planning and psychosocial support: German Neurological Society guideline

> “Early in the disease process, it is recommended to document living wills and care directives”
> “Moreover, there should be support from a social worker to navigate the complex bureaucracy to apply for and obtain financial assistance and support for care needs.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.4-10"></a>

###### Advance care planning: multicenter HDQLIFE study

> “Most importantly, engaging in ACP does not cause untoward effects on HRQoL or STB for this rare neurodegenerative disease where the lifetime prevalence of STB approaches 30%.”

Source: [Sokol et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10036076/)

<a id="topic-2.2.2.4-11"></a>

###### Palliative care in advanced disease: scoping review

> “Our search resulted in 333 articles, 38 of which were included.”
> “Most literature was underpinned by a low level of evidence, except for the topics on social care (Level III-V), advance care planning (Level II-V) and end-of-life needs assessments (Level II-III).”

Source: [Boersema-Wijma et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10155365/)

<a id="topic-2.2.2.4-12"></a>

###### Palliative care across disease stages

> “But for those with pain, anxiety, sleep disturbances, and difficulty coping with their diagnosis, referral to palliative care should be strongly considered.”

Source: [Tarolli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5395679/)

Additional sources: [El-Sourady et al. (2022)](https://journals.sagepub.com/doi/full/10.1089/jpm.2021.0308); [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36698999/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
- Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
- Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
- Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/); [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [FDA externally controlled trials draft guidance (2023)](https://www.fda.gov/media/164960/download); [Jahanshahi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/); [Hernandez (2025)](https://en.hdbuzz.net/483-additional-clarity-what-we-know-4-weeks-after-the-uniqure-news/); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)

<a id="topic-2.2.2.7-2"></a>

###### Durability of a one-time gene therapy: ICER modeling assumption and clinical expert input

> “Clinical experts noted that because neurons do not divide, the treatment effect may persist and not dilute over time.”
> “However, substantial uncertainty remains around long-term efficacy”
> “The treatment effect will be assumed to remain constant over the lifetime horizon.”
> “As AMT-130 is a one-time gene therapy, discontinuation will not be modeled.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.7-3"></a>

###### Link between cUHDRS and long-term outcomes: ICER rationale for modeling Total Functional Capacity

> “Although TFC may not fully capture cognitive and neuropsychiatric symptoms related to HD, there is currently no established mapping between measures such as the cUHDRS to costs, utilities or mortality.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.7-4"></a>

###### Procedure-related outcomes in the ICER assessment

> “The outcomes of interest are described in the list below.”
> “Adverse events including:”
> “Procedure-related adverse events (e.g., headache, complications, pain)”
> “Post lumbar puncture syndrome”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.7-5"></a>

###### Placebo and practice effects when trial data are compared with natural history

> “Of interest, the cognitive scores (SDMT, SWR) exhibited an even stronger placebo response that was sustained after the dosing period of the trial ended.”
> “It is important to note that these effects also significantly influence the cUHDRS score, given that it is derived from a linear relationship between TFC, TMS, SDMT score, and SWR score.”
> “However, our analysis also emphasizes the potential for misleading interpretations when comparing trial data with retrospective natural history studies, particularly in distinguishing placebo response from drug effect.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.2.7-6"></a>

###### Interpretation of externally controlled comparisons: FDA draft guidance

> “Scenarios that would not be suitable for externally controlled trials include when the natural history of the disease of interest is not understood sufficiently or when the disease course is considered well-understood but is variable.”
> “Changes over time in the understanding of the natural history of a disease can also introduce bias in an externally controlled trial.”

Source: [FDA externally controlled trials draft guidance (2023)](https://www.fda.gov/media/164960/download)

<a id="topic-2.2.2.7-7"></a>

###### External controls in FDA approvals, 2000 to 2019: sources and endpoints

> “Forty-five approvals were identified where FDA accepted external control data in their benefit/risk assessment”
> “Retrospective natural history data, including retrospective reviews of patient records, was the most common source of external control (44%).”
> “The vast majority (87%) of cases identified utilized an objective measure as a primary endpoint.”
> “For the few cases where the endpoint was subjective, the benefit was so large it was unlikely to be due to chance alone.”

Source: [Jahanshahi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/)

<a id="topic-2.2.2.7-8"></a>

###### Independent commentary on the natural history comparator and durability of AMT-130

> “The people in this trial could be going to the clinic more frequently than those in the Enroll-HD comparator group, causing a medical response bias that improves their symptoms.”
> “So for a Phase 1/2 trial like this one for AMT-130, a natural history comparator can give us an idea if a drug is meeting certain metrics, but isn’t robust enough to conclusively tell us if a gene therapy is effective.”
> “Even with the permanence of this treatment, how durable will it be? Will it wear off over time?”
> “Key questions remain: durability of benefit, variability of response, affordability, and future accessibility.”

Source: [Hernandez (2025)](https://en.hdbuzz.net/483-additional-clarity-what-we-know-4-weeks-after-the-uniqure-news/)

<a id="topic-2.2.2.7-9"></a>

###### Natural history-based evidence and assumed duration of benefit: Prilenia comment to ICER

> “Prilenia thanks ICER for the opportunity to submit input at the scoping stage of this assessment.”
> “AMT-130’s evidence relies on comparing treated patients to a propensity-matched group from Enroll-HD although the original design includes a 1-year placebo arm.”
> “While Enroll-HD is a strong registry, this type of natural-history comparison has built-in limits: important patient differences that can’t be matched, such as caudate and putamen size (a key prognostic inclusion criterion absent from Enroll-HD), bias from who chooses to enter a surgical trial versus a registry, different visit schedules, possible behavior changes after surgery, and very small numbers of treated patients at longer follow-up.”
> “For AMT-130, assumptions about how long the benefit lasts will heavily shape the results.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.7-10"></a>

###### Composite clinical progression measure in early Huntington's disease

> “Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-2.2.2.7-11"></a>

###### Clinically meaningful change on the cUHDRS

> “Analyses anchored against CGI-S and IS support that a decline on the cUHDRS of 1.2 points is clinically meaningful, and that the cUHDRS tracks function decline.”
> “Based on these values, a decline of 1.2 points is recommended as an estimate of meaningful within-patient decline for use in a responder analysis endpoint in clinical trials in patients with early manifest HD.”

Source: [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf)

<a id="topic-2.2.2.7-12"></a>

###### Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback

> “The FDA continued to support its prior agreement that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.2.2.7-13"></a>

###### Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD

> “The primary endpoint will be the change from baseline up to month 36 in the cUHDRS.”

Source: [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)

<a id="topic-2.2.2.7-14"></a>

###### Time to functional decline as an endpoint

> “A delay of 9 months or more in the transition to Stage 3 for an enriched sample yields feasible sample size estimates, demonstrating that this approach can aid in planning future trials.”

Source: [Mills et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39101272/)

<a id="topic-2.2.2.7-15"></a>

###### Cognitive endpoints and regulatory meaningfulness

> “Thus, improvements or declines in performance on the SDMT alone are not sufficient for demonstrating meaningful effects that could lead to regulatory approval of a treatment.”

Source: [Roiboit and Stout (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12839483/)

<a id="topic-2.2.2.7-16"></a>

###### Aims of disease-modifying treatment and modeled long-term outcomes

> “Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.”
> “Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.”

Source: [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)

<a id="topic-2.2.2.7-17"></a>

###### Expected outcomes of symptomatic chorea treatment

> “By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.”

Source: [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)

Additional sources: [Trundell et al. (2019)](https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P1.8-043)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
